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ABSTRACT
Difficult-to-express (DTE) recombinant proteins like multi-specific proteins, DTE monoclonal
antibodies and lysosomal enzymes, have seen difficulties in manufacturability using Chinese
hamster ovary (CHO) cells and other mammalian cells as production platforms. CHO cells are
preferably used for protein production because of their innate ability to secrete human-like
recombinant proteins with post-translational modification, resistance to viral infection and
familiarity with drug regulators. However, despite huge progress made in engineering CHO
cells for high volumetric productivity, expression of DTE proteins like recombinant lysosomal
sulfatase represent one of the poorly understood proteins. Furthermore, there are growing
interest in the use of microRNAs (miRNAs) to engineer CHO cells expressing DTE proteins
to improve cell performance of relevant bioprocess phenotypes. Therefore, we sought to
understand miRNA expression profiles in CHO cell lines stably expressing DTE lysosomal
protein and examined the effect of microRNA-engineering of these cell lines on protein
expression.
Firstly, we utilized next generation sequencing (NGS) technology for an integrated mRNA and
microRNA profiling of three CHO cell lines (including parental cell) stably expressing a DTE
lysosomal protein cultivated in a biphasic fed-batch mode within a 5L Dasgip bioreactor. With
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exception to the parental cell line, the other two cell lines differ by their productivity and were
identified as low and high producers. Following RNA-seq and small RNA-seq data analyses
by the Bioinformatics group at BioMarin, among other analyses, correlation and differential
analyses identified 500 mRNA and 35 miRNAs that were differentially expressed in these cell
lines over cultivation period. This study identified miRNAs that are potential targets for
engineering of CHO cells for the enhancement of DTE protein expression. Secondly, in an
independent study, we identified miR-23a and miR-377 as miRNAs targeting sulfatase
modifying factor 1 (SUMF1) by using in silico prediction tools as SUMF1 is an activator of
sulfatases. Transient inhibition of endogenous miR-23a/miR-377 significantly enhanced
recombinant sulfatase enzyme specific activity in CHO cells without affecting cell growth.
Though, inhibition of miR-23a/miR-377 had no significant effect on the mRNA and protein
levels of SUMF1, overexpression of miR-23a/377 significantly reduced both the mRNA and
protein levels of SUMF1. In summary, our data demonstrates the importance of using miRNA
to optimize protein expression in CHO cells secreting DTE recombinant lysosomal proteins.
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CHAPTER 1

1.0

INTRODUCTION AND LITERATURE REVIEW

The increase in production of more complex, difficult-to-express (DTE) recombinant
therapeutic proteins e.g. multi-specific proteins, fusion proteins, membrane proteins,
lysosomal enzymes and other DTE monoclonal antibodies (mAb) have seen difficulties in
manufacturability using CHO cells or other mammalian cells as production factories (Kelly et
al. 2014; Migani, Smales, and Bracewell 2017). Mammalian cells are preferably used for the
production of most proteins because of their ability to produce proteins with human-like posttranslation modification (PTM), their resistance to viral infection and popularity with drug
regulators. Lysosomal enzymes represent one of the least studied or reviewed recombinant
therapeutic class of proteins compared to monoclonal antibodies (mAbs) and other well
understood proteins manufactured as biologics. In the early years of lysosomal enzyme
production as a biopharmaceutical, CHO cells production of lysosomal enzyme could be as
low as 20,900 U/mg (~100 micrograms of enzyme/107 cells) produced, secreting ~ 13,000 U
(or 75 µg/107 cells) per day (Ioannou, Bishop, and Desnick 1992). Of recent, the productivity
yield has increased (e.g. 0.05-0.25 mg/mL of GAA production) as a result of advances in
bioprocessing process parameter control, media formulation and genetic engineering (Migani,
Smales, and Bracewell 2017). In spite of these advances the full potential of the mammalian
host systems used in the production of DTE lysosomal proteins have not been completely
utilized. At this time point, engineering of the mammalian host system might represent a viable
route to increasing production yield of DTE lysosomal proteins. The lysosome which acts like
the recycle warehouse of the cell, contains proteins that breakdown glycosaminoglycans
(GAG) and other macromolecular substrates. Mutations in the gene coding for any of these

1
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lysosomal enzymes or proteins can lead to the accumulation of these substrates in the
lysosome leading to a disease state termed lysosomal storage disorder (LSD). An example
of these diseases among others is multiple sulfatase deficiency (MSD) caused by mutations
in sulfatase modifying factor (SUMF1), a gene that encodes formylglycine –generating
enzyme (FGE). A difficult-to-express protein could arise as a result of insolubility, improper
folding, aggregate formation (e.g. variable region of dimeric Fab antibody), and issues
stemming from protein half-life, production yield and stability. In the world of rare diseases –
lysosomal storage disorders (LSD), producing active form of lysosomal protein could
sometimes pose a challenge to scientists
The role of microRNA in cancer and autoimmune diseases is well researched unlike its
application in bioprocessing for protein expression purposes. MicroRNAs (miRNAs) has been
shown to play critical roles in many cellular processes – differentiation, development, cellular
growth, apoptosis, including the expression of transcription factor EB (TFEB) that regulates a
gene network called Coordinated Lysosomal Expression and Regulation (CLEAR) (de
Queiroz et al. 2016). A handful of work has been done linking non-coding RNA to gene
expression in lysosomal storage diseases (LSD). Generally, microRNAs can be located
between exons or introns of the genome. They tend to destabilize or inhibit the translation of
their mRNA target by imperfectly binding to the 3’ UTR of the mRNA target. MicroRNA effect
on CHO cells that has been a subject of intense research currently and it has been observed
that as CHO cells behavior defer by the kind of protein they express and/or clonal variation,
miRNA expression profiles changes (Maccani et al. 2014). Diiferent methods have been
developed for the identification of miRNA expression relative to protein expression: microRNA
library screen, mRNA and miRNA microarray, next-generation sequencing (Inwood,
Betenbaugh, and Shiloach 2018)

2
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1.1

Bioprocessing - production of therapeutic proteins

Recombinant therapeutic proteins are usually produced in large scale via a process called
bioprocessing. Bioprocessing, in the context of protein production, entails the use of living
organisms to produce recombinant therapeutic proteins – antibodies, fusion proteins,
anticoagulants, growth factors, hormones, interferons, enzymes, vaccines. The protein
production process involves multiple stages from selection of expression host system to the
use bioreactors for production. The choice of expression host like mammalian cells (e.g.,
Chinese hamster ovary cell (CHO), human embryonic kidney cells (HEK), Escherichia coli,
insect cells, yeast, hybridomas etc.) depends on: the type of biopharmaceutical product (e.g.
membrane protein, glycosylated proteins), post-translation modification (PTM) requirement,
ease of use, protein stability and solubility, timing, cost, and familiarity with regulators among
others.

1.2

MicroRNA

MicroRNAs (miRNAs) are short non-coding ribonucleic acid (RNA) molecule, about 18-24
nucleotide in length. They negatively regulate genes post-transcriptionally, regulating onethird of the genes in eukaryotic cells without adding any translational burden on the cell
machineries unlike protein coding genes when overexpressed. MiRNAs regulate genes by
binding imperfectly (one or two base pair difference) to the 3' untranslated region (UTR) of
their target mRNA with mismatches and bulges causing repression or a perfect binding
causing degradation by the miRNA-induced silencing complex (miRISC) (Ha and Kim 2014).
The 5' end of miRNA at nucleotide 2 to 8 contain a domain region called “seed region” for the
recognition of target mRNA. Though in plants, microRNAs bind to their targets in a near-
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perfect manner inducing the cleavage of mRNA targets by endonuclease (Pasquinelli 2012).
Though a rare example of near-perfect complementarity has been mentioned for animals in
which miR-196 binds to HOXB8 mRNA (Pasquinelli 2012).
One major feature of MicroRNAs is their known conservative characteristics across species,
and even as similar target recognition seem to be conserved in mammalian cells (Friedman
et al. 2009). MiRNAs can either be downregulated or overexpressed where alterations in their
levels can cause changes in cell phenotypes. They have been described as molecules that
fine tune gene expression in eukaryotic cells (Baek et al. 2008) and have been shown to play
vital roles in cellular processes like differentiation, proliferation, development , and apoptosis.
Alterations in the levels of miRNA has been linked to various diseases, in most cases cancer
(Wang, Wei, and Sarkar 2012). These findings are prominent in cancer research for over two
decades now and protein expression scientists are currently exploring ways to tap into the
potentials of miRNAs as global gene regulators in the field of bioprocessing. Techniques like
crosslinking and immunoprecipitation (CLIP) and ribosome profiling have been employed to
understand miRNA binding sites and its targets (Pritchard, Cheng, and Tewari 2012). Different
culture conditions (nutrient depletion, temperature shift) has been shown to cause changes in
miRNAs levels in profiling studies in a bioprocessing system (Druz et al. 2013; N. Barron et
al. 2011).
For example, Strotbek et al (2013) were able to demonstrate that miR-557 and miR-1287
improved growth profile (VCD) and specific productivity (qP) respectively in CHO cells
expressing IgG1 proteins. The CHO cells engineered with these miRNAs exhibited higher
IgG1 titer while retaining product quality. In addition, the CHO cells exhibited a much higher
protein titer and specific productivity when the miRNAs were co-transfected (Strotbek et al.
2013).
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1.2.1

MiRNA Biogenesis:

MicroRNAs are transcribed by Polymerase II (Pol II) into a primary transcript (pri-miRNA) that
is about 72 nucleotide in length inside the nucleus of the cell (Figure 1). Thereafter, it is
processed by a microprocessor complex- Drosha and its cofactor DiGeorge syndrome critical
region gene 8 (DGCR8 or Pasha), into a hairpin precursor microRNA (pre-miRNA) which is
then transported into the cytoplasm by RanGTP-dependent exportin-5 (XPO5) protein. While
in the cytoplasm, the loop of the pre-miRNA is removed by DICER/Tar RNA binding protein
(TRBP) complex forming a microRNA duplex- guide and passenger (or star) strands that is
21-24 nucleotide long. The resulting microRNA duplex is later bound by argonaute protein
forming the miRNA-induced silencing complex (miRISC), includes GW182 proteins, which is
directed by the guide strand to mRNA target for regulation. The star strand (miRNA*) is
degraded and the guide strand binds to the target mRNA through partial complementarity with
bulges resulting in repression of translational initiation or cleavage of the target mRNA in some
rare occasion of near perfect complementarity e.g., miR-196 targeting HOXB8 mRNA
(Pasquinelli 2012). The selection of the strand destined for degradation is dependent on the
thermodynamic stability of the 5’ end (Pasquinelli 2012; O’Brien et al. 2018; Ha and Kim 2014).
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Figure 1: Canonical pathway of microRNA biogenesis. Image used and adapted from Winter et al.
(2009)(Winter et al. 2009)

1.2.2

Mechanism of action

The effect of synthetic microRNA inhibitors on cell physiology is dependent on abundance of
endogenous microRNA expression it is inhibiting. MicroRNA recognizes its target by binding
to the 3’ UTR of the mRNA target. Though there are reports that revealed binding to the
mRNA target at the 5’ UTR (J. Robin Lytle, Therese A. Yario 2000), protein coding region,
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and 3’ UTR. Though there are reports that miRNAs can also upregulate the expression of
their target genes as against their nominal function of negatively inhibit gene expression
(Vasudevan 2012).
1.2.3

Methods of engineering mammalian cells using miRNA

In most cases, transient transfection of microRNA mimics or inhibitors into mammalian cells
is performed by lipid-mediated transfection method. To efficiently assess transfection
efficiency of the transfection reagent used it is pertinent to assess the effect of the miRNA
mimic or inhibitor on their target mRNA/protein in addition to using flow cytometry or
fluorescence microscopy. The reason is that using flow cytometry or florescence microscopy
alone could give a false positive result because the transfected microRNAs could be stalked
in the endosome, firmly bound with the transfection reagent and not being released in order
to be bound with the miRISC complex for mRNA targeting (Fischer et al. 2013). Interestingly,
assessing transfection efficiency by measuring the levels of miRNA mimics using qRT-PCR
might not really portray the accurate amount of functional or active miRNAs bound to
Argonaute protein, while microRNA inhibitors could inhibit qPCR reaction. Using qRT-PCR
alone might only be measuring the amount of both vesicular (inactive) and Argonaute-bound
(active) mimics (Thomson et al. 2013). Thomson et al. 2013 used Argonaute:miRNA
immunoprecipitation assay to accurately assess functional or active microRNAs post transient
transfection of microRNA mimics.
1.2.3.1

mRNA and miRNA profiling of CHO cells

To generate a better understanding of the transcriptome (mRNA or miRNA) of CHO cells,
scientists are using high throughput technologies (e.g. next-generation sequencing,
microarray technology, liquid chromatography/mass spectrometry (LC/MS) and miRNA
library) in combination with cell cultivation (suspension or static) and different cell culture
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modes (fed-batch, batch or steady state)(Table 2). Only of recent was the CHO genome was
sequenced providing more opportunities to understand the biology of this important host cell.
Profiling of CHO cells using these technologies have providing much characterization of CHO
cell lines and context for cell engineering purposes. Although, these profiling techniques have
their advantages and disadvantages (Table 1) (Pritchard, Cheng, and Tewari 2012)
Table 1: Advantages and disadvantages of miRNA profiling technologies and their

commercially available platforms*
MiRNA Profiling

Advantages

Disadvantages

Platforms

Technologies
MicroRNA microarray  Low cost and high throughput
 Affordable

 Lower specificity compared to
qRT-PCR or RNA sequencing
 Cross hybridization between
probes and sample
 No detection of novel miRNAs

Genome Biochip miRNA,
GeneChip miRNA array,
GenoExplorer, MicroRNA
microarray, miRCURY LNA
microRNA array, OneArray,
uParaFlo biochip array

RNA sequencing

 No cross hybridization
between samples
 Higher sensitivity detecting
very less abundant genes

 Required expertise for
computational analyses of data
 Cannot be used for absolute

HTS: HiSeq 2000, SOLiD,
GS FLX+ (454
sequencing)

quantification
Small-scale: Ion Torrent,

(Stiefel et al. 2016)

MiSeq, GS Junior (454)

 Broader dynamic range. Can
detect novel miRNAs
qRT-PCR

 No cross hybridization
between samples

 Cannot identify novel miRNAs

Taqman individual

 Medium throughput with

assays, miRCURY LNA

 High sensitivity and specificity

respect to number of samples

qPCR, TaqMan TLDA

 Can be used for absolute

processed per day

microfluidics card,

quantification

Biomark HD system,
SmartChip human
microRNA, miScript
miRNA PCR array

*Table modified from Pritchard, Cheng and Tewari (Pritchard, Cheng, and Tewari 2012)
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Table 2: mRNA and miRNA profiling experiment conducted on CHO cell host platforms
Profiling

Cell Line Used

Cell Type

Technique
Human

CHO-DG44

Suspension

Protein

Cultivation

Secreted

mode

Human serum

Fed-batch

microRNA

albumin (HSA) or

library

mAb IgG1

Small RNA

CHO-K1

Adherent

sequencing

References

(Strotbek et al.
2013)

Secreted alkaline

Media

(Hammond et al.

phosphatase,

supplemented

2012)

tissue (SEAP),

with 10% FBS

plasminogen
activator (tPA)
miRNA

CHO-DUKX-B11

Suspension

microarray

3D6 single-chain

Steady state

Fv-Fc fusion

(Maccani et al.
2014)

antibody, Human
serum albumin
(HSA)
miRNA

CHO-K1, CHO-S

Static

Human IgG1

nil

microarray
qPCR +

(Harreither et al.
2015)

CHO

Suspension

mAb

Batch

Microarray +

(Clarke et al.
2012)

Quantitative
LC-MS/MS
mRNA &

CHO-K1

Suspension

IgG1

Batch

(Bort et al. 2012)

CHO-K1

Suspension

mAb

Fed-batch

(Meleady et al.

miRNA
microarray
LC-MS/MS

2011)
Small RNA

CHO-K1 (serum-

deep

dependent), CHO-

sequencing

k1 (serum –free),

CHO-K1(serum

CHO-DUXB11

free) -mAb

Static

DUXB11-Epo-Fc

nil

(Hackl et al.
2011)

(serum-free)
miRNA

CHO-K1, CHO-

Static,

microarry

DUKXB11, and

suspension

Epo-Fc

nil

(Klanert et al.
2016)

CHO-S (among
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serum, serum-free,
L-Glutamine)
Small RNA

CHO-DG44

Suspension

mAb

sequencing

1.2.4

Fed-batch

(Stiefel et al.
2016)

MicroRNA-engineering of CHO cells

Mammalian cells are the preferred choice of cell factories for the manufacturing of biologics
because of their ability to make proteins with similar posttranslational modifications (PTM) to
that of humans unlike bacteria and yeast cells. However, mammalian cell factories or
expression systems still grapple with the hurdle of an optimal protein yield. In addition, due to
the growing demands of biologics and incremental development of new technologies scientist
testing boundaries searching for more ways to optimize mammalian cells most especially
CHO cells. Subsequently, different approaches like cellular engineering, process engineering
(Alves et al. 2015), media optimization and genetic engineering have applied to CHO cells to
optimize productivity. Common trend in genetic approach is the overexpression of a gene of
interest which invariably adds more translational burden to the cell machinery. There are
growing interest among the scientific community of using miRNA to engineer CHO cells since
this approach do not add extra translational burden and the actions of one miRNA could have
effect on more than one pathways. Engineering CHO cells with miRNAs have been applied in
to improve different cellular processes such as apoptosis (Druz et al. 2013), protein production
(Loh, Yang, and Lam 2017; Chen et al. 2005; Fischer, Paul, et al. 2015; Kelly et al. 2015;
Meyer et al. 2017; Emmerling et al. 2016; Loh et al. 2014), growth rate (N. Barron et al. 2011)
1.2.4.1

MicroRNA engineering of CHO cells expressing difficult-to-express (DTE) protein

Proteins are said to be difficult-to-express (DTE) if they are insoluble making it difficult for
downstream characterization and analyses e.g. Western blotting and purification. Improper
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folding (or misfolding) of proteins as well as aggregate formation could be troubling when
using producing these proteins especially for commercial purposes. The fusion of human
serum albumin (HSA) or Fc to the N-terminus of DTE protein helped I mitigating insolubility
(Carter et al. 2010). Co-expression of molecular chaperones (BiP, PDI, CypB), unfolding
protein response (UPR) and chemical chaperones (PBA, DMSO, glycerol) have been used to
mitigate aggregation problems (Johari et al. 2015). Moreover, in the case of enzymes, most
of it could exist in their inactive form. Lastly, expressing a low yield protein is one of the most
common problems and scientists are using cellular and process engineering methods to solve
this problem. Previous studies have shown that CHO-K1 has a larger ER and higher
mitochondrial mass than CHO DUXB11 which might indicate reason why CHO-K1 gives better
yield.
Of recent, scientists are using miRNA to engineer CHO cells secreting DTE proteins (e.g.
lysosomal proteins, membrane proteins- neurotensin receptor type 1 (NTSR1) and serotonin
transporter (SERT) in order to improve relevant bioprocess phenotypes like productivity
(Inwood, Betenbaugh, and Shiloach 2018; Pybus et al. 2014; Schoellhorn et al. 2017; Fischer
et al. 2017, 2013).
1.3

Difficult-to-express lysosomal enzymes

Lysosomal enzymes are proteins in the lysosome of most eukaryotic cells and are responsible
for the breakdown of cell waste products, carbohydrates, lipids, proteins, nucleic acids which
are then returned to the cytoplasm. They are produced in the endoplasmic reticulum and
modified in the Golgi apparatus. The enzymes are destined for the lysosome since they are
tagged with mannose-6-phosphate (m6PO4) which binds with mannose-6-phosphate
receptors which directs the enzyme to the lysosome with aid of other mechanisms. Though
some of the enzyme may not require m6PO4 receptor for trafficking reason why β-
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glucoerebrosidase had its mannose terminated and successfully produced in CHO cells
(Desnick and Schuchman 2012). Deficiency in these enzymes can cause the accumulation of
their substrate in the lysosome of the cells leading to conditions known as lysosomal storage
disorder (LSD).
Since prokaryotic cells do not execute post-translational modification (PTM) of proteins, CHO
or other mammalian cells have become the host platform of choice in the manufacturing of
lysosomal enzymes. Lysosomal enzymes require PTM for their stability and activity.
Production of lysosomal enzyme could be difficult as it has been reported that not all
overexpressed recombinant enzyme in a CHO host are successfully secreted into the
surrounding culture medium. Consequently, production of a large batch will be required
leading to a high cost of production (Ioannou, Bishop, and Desnick 1992; Desnick and
Schuchman 2012). Examples of lysosomal enzymes are: glycosidases, protease, sulfatases,
acid phosphatases and lipases etc.
Aim and scope of research
Though CHO cells have been the commonly used mammalian cell line for the production of
recombinant therapeutic protein scientists still believe that the production capacity limit of this
workhorse has not been reached. Different cellular, process and genetic engineering means
has been used to make this happen. Currently, protein expression scientists are tapping much
of the knowledge of miRNA garnered from cancer research and applying that to CHO or other
mammalian cell engineering to induce relevant bioprocess phenotypes. One key factor that
really promoted this research was the sequencing of the CHO genome, which promoted
profiling and cellular engineering of different CHO cell lines. The advantage of using miRNA
over gene expression for engineering purpose is that it does not add an extra translational
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burden to the machineries of the cell. The scope of this research will rest on the profiling and
miRNA-engineering of CHO cell line stably expressing a DTE lysosomal enzyme.
Significance of research
The miRNAs and mRNA identified from the next-generation sequencing experiment of CHO
cell lines expressing DTE lysosomal enzymes will provide the scientific community potential
list of targets for cell engineering for the improvement of cell growth and volumetric
productivity. In addition, it provided substantial knowledge of miRNA dynamic changes in
CHO cell lines that vary in their growth rate and specific productivity.
Furthermore, identifying sulfatase modifying factor 1 (SUMF1) as a target to miR-23a-3p and
miR-377-3p and observing an improvement in sulfatase activity by inhibiting these miRNAs
demonstrate the importance of using miRNA to effect desirable bioprocess qualities in CHO
cells. This observation could provide a context for research of these miRNAs in clinical
research
Overview of the study
This thesis is written in chapters. Chapter 1 has the introduction and literature review. It consist
of overview on bioprocessing, microRNA, its origin, mechanisms of action and its application
in engineering difficult-to-express proteins. Lastly it contains the aim, scope and significance
of the research
Chapter 2 highlights the hypothesis and objective of the research. Chapter 3 contains full
description of the materials and methods. Chapter 4 and Chapter 5 contain miRNA/mRNA
profiling research and miRNA engineering experiment respectively.
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CHAPTER 2

2.0

RESEARCH OBJECTIVES

Hypothesis
MiRNA has been proven through research to have the ability to regulate major cellular
processes in the cells that are relevant to bioprocessing phenotypes of CHO cells as
production host. Developing a good understanding of miRNA expression dynamics will
help in identifying selected miRNAs as engineering targets whose impact on CHO cell
could potentially improve relevant bioprocess phenotype(s).

Research Objectives
1. Identify potential miRNAs as targets for downstream CHO cell engineering by
transcriptomic profiling of in house CHO cell stably secreting a difficult-to-express (DTE)
enzyme
2. Identify potential miRNAs that targets sulfatase modifying factor 1 (SUMF1) and
evaluate their effect on sulfatase specific activity
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CHAPTER 3

3.0

MATERIALS AND METHODS

3.1

CELL CULTURE TECHNIQUES AND TRANSFECTION

3.1.1

Biosafety cabinet

Cell culture work were performed in a Logic+ laminar flow biosafety level II cabinet (Labconco,
G3371028) to prevent contamination from airborne particulates. Before any cell culture work,
the work area inside the cabinet was wiped down with 70% isopropyl alcohol (IPA). All media
bottles and cell culture flasks were all wiped down with IPA to prevent transferring
contaminants into the cabinet. At the end of all cell culture work, the cabinet was wiped down
again with IPA and sash closed.
3.1.2

Cell Thawing

The frozen cells were retrieved from liquid nitrogen and thawed using a liquid water bath (Lab
Armor) with gentle swirling or the use of ThawStar thawing system (Biocision). The thawed
cells were pipetted and transferred to a T-75 flasks containing 10 mL of media pre-warmed at
37⁰ C. Flask was transferred to a static incubator kept at a temperature of 37⁰ C, 5% CO2 and
8% humidity for 24 hours. The cells were pelleted by centrifugation at 250 x g for 5 minutes
and re-suspended in a fresh media for subsequent culturing in order to remove traces of
DMSO contained in cell freezing media.
3.1.3

Cell Freezing

Cells for cryopreservation were counted and harvested when the cell concentration was at
about 4.0e6 cells/mL of the exponential cell growth phase. The cells were pelleted by
centrifugation at 250 x g for 5 minutes and supernatant discarded. 1 mL of cryopreservation
media was added to re-suspend every 10e6 cells pelleted. 1 mL of the mixture containing
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10e6 cells was transferred to a cryovial and stored at -80⁰ C overnight. It was transferred the
following day to a liquid nitrogen kept at -180⁰ C for long term storage.
3.2

Passaging of cell lines

3.2.1

Adherent cells

Cell splitting were done at a ratio of 1:2 when the cells have reached confluency of 80-90%.
Before splitting, spent media was removed with a glass pipette or aspirated before rinsing with
sterile 1X DPBS (Corning, 21-031CV) to remove any residual phenol contained in the media
that will dampen the effect of TrypLE Express (ThermoFisher Scientific, 12605-028), for cell
dissociation. After the addition of 2-5 mL TryPLE Express, the flask or plate was transferred
to a humidified HERAcell Vios 160i (Thermo Scientific) static incubator kept at 5% CO2 and
37⁰ C for 2-4 minutes. The flask was observed under the Evos XL core microscope (Life
Technologies) to make sure all cells have dissociated and assumed a circular morphology.
About 3 - 20 mL serum-containing media were added into flask to keep the cells in suspension
and pipetted out into a 15 or 50 ml tube depending on the size of the flask. These tubes were
then centrifuged at 250 g for 5 minutes. After centrifugation, the supernatant was discarded
and the cell pellet re-suspended in a fresh serum-containing media. 20 mL fresh media was
used for cells split equally into two T-75 flask (Corning) and 30 ml media for cells split equally
into two T-175 flask (Corning).
3.2.2

Suspension cells

Cells to be passaged were first counted on the ViCell™ XR (Beckman Coulter) to obtain viable
cell density and viability values. Cells were passaged every 3-4 days at a seeding density of
0.5 x 106 cells/mL. The volume of cell culture required to seed cells were aliquoted into a new
flask and fresh pre-warmed (37⁰ C) media was added at the required volume. The flask was
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transferred to a stackable incubation shaker (Multitron Pro, Infors HT) maintained at 37⁰ C in
atmospheric CO2 of 5% and 80% humidity for 3-4 days with 125 rpm rotation before
passaging.
3.2.3

Cell counting

3.2.3.1

Vicell™ XR cell viability analyzer

500 uL of cell culture from cells grown in flask was aliquoted into a sampling cup and inserted
into the ViCell™ XR (Beckman Coulter) sample cup holder for determination of the
concentration of cells, viability and cell size. The ViCell uses the Trypan Blue exclusion
principle by counting cells stained with dye as dead cells.
3.2.3.2

Nucleocounter NC-200

Cell culture sample from cells grown in 6-well plates was loaded into vial cassette
(Chemometec, 941-0011) by dipping the sterile cassette tip into the well containing
suspended cells and pressing the piston to aliquot sample (~1.4ul used) into the cassette.
The undulating shape of the mixing channel in the cassette allows the sample to mix very well
with acridine orange and DAPI dyes contained in this channel. The acridine dye stains all
cells, while DAPI stains all non-viable cells. After aliquoting the cell sample, the cassette was
inserted into the NC-200 cassette holder and sample analyzed by pressing the “run” button.
3.3

Transfection

3.3.1

Transfection of siRNA/microRNAs with lipid-base reagent method

Transient transfection of suspension cells were carried out by seeding and transfecting the
cells on the same day (reverse transfection). For adherent cells, the cells were seeded 24
hours before transfection (forward transfection). Following manufacturer’s protocol,
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transfection of suspension cells (e.g. CHO or HEK293 cells), were carried out on the day of
transfection by seeding 2.5 mL of cell culture at a concentration of 0.3 - 0.8e6 cells/mL
(depending on what cell line was used) in each required well of a 6-well plate. Transfections
were carried out in duplicates. All components required for transfection were used in 5-10%
excess to compensate for loses due to pipetting. A master mix of microRNA mimic/inhibitor
or siRNA was created by diluting 7.5 uL of miRNA mimic/inhibitor or siRNA (20μM) with 485
uL of Opti-MEM I reduced serum media (Gibco, 31985070) in a 5 mL DNA Lobind tube
(Eppendorf, 0030108310). The mixture was mixed gently. Lipofectamine

TM

RNAiMax

(Thermo Scientific, 13778150) reagent was mixed gently before use. 7.5 uL of Lipofectamine
RNAiMAX were added to the tube containing mixture of miRNA mimic/inhibitor or siRNA and
Opti-MEM I reduced serum media for complex formation. The mixture was allowed to incubate
for 10-20 minutes at room temperature. After incubation, 500 uL from the mixture was added
to each well containing 2.5 mL of 0.3-0.6e6 cells/mL of cells giving a final volume of 3 mL and
final concentration of 50 nM. Each 6-well plate was mixed gently by rocking back and forth.
Plates were kept in a static incubator for 96 hours.
3.3.2

Transfection of plasmid DNA (pDNA) using electroporation method

Transient transfection was carried out by using Maxcyte STX scalable transfection system
(MaxCyte) for adherent or suspension cells. Adherent cells were trypsinized with TrypLE
Express (Thermo Scientific, 12605-028) and neutralized with cell media and mixture
transferred to a 15 mL tube. However, for suspension cells, the cells were transferred directly
to a 15 mL tube. With a target cell culture volume of 30 mL, 20e6 cells in suspension were
spun at 250 x g for 5 minutes and supernatant discarded. Cell pellet was rinsed in 1.5 mL of
electroporation buffer (Maxcyte, B201-100) and pelleted again at 250 x g for 5 minutes. While
the cells were being spun, 20 μg of pDNA was aliquoted into a 1.5 mL microcentrifuge tube
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and the OC 400 processing assemblies (PA) were labeled based on experimental design. The
cell pellet were dissolved in the right volume of electroporation buffer (400 uL less volume of
plasmid used) and mixed with the plasmid by gentle up and down pipetting. The mixture were
transferred to a PA in a final volume of 400 uL avoiding the generation of air bubbles and
made sure the liquid was in full contact with both sides of the PA. The PA were inserted into
the Maxcyte STX system and the cell transfection protocol was selected depending on what
cell line was used. After electroporation, the PA was removed from the STX system and the
electroporated cells were transferred to an empty 30 mL Ehrlenmeyer flask (Corning). 5ml of
required cell culture media was added to the 400ul electroporated cells contained in the 30ml
flask and incubated in a static incubator at 37⁰ C for 20 - 30 minutes. After incubation, 24.6
uL of additional media was added to the flask, which brought the cell density to about 0.3 –
0.6e6 cells/mL. Cells were cultured either in a 6-well plate or cell culture flask.
3.3.3

Cell Imaging/Transfection efficiency measurement

Green fluorescent protein (GFP) plasmid and small-interfering RNA (siRNA) Block-iT Alexa
Fluor 555 red fluorescent control were used as indicators to assess transfection efficiency in
a lipid-mediated or electroporation transfection method. Media from the well of a 6-well plate
containing cells transfected with GFP or Alexa Fluor were aspirated and about 1 mL of 1X
DPBS was added in order to eliminate any color background generated by the media when
viewed under the EVOS FL Auto fluorescence microscope (Life Technologies). The cells
transfected with GFP or Red Alexa Fluor were viewed under the fluorescent channel for GFP
or Texas Red (RFP) respectively. The images obtained were viewed under 10X, 20X or 40X
magnification.
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3.4

MOLECULAR BIOLOGY TECHNIQUES

3.4.1

Molecular biology water

Water for preparing solutions used for assays were made using ultrapure water. The ultrapure
was generated from Milli-Q-Advantage A10 water purification system (Millipore). Hypure
molecular biology grade water (GE, SH30538.01) was used for reconstituting or rehydrating
antibodies and oligonucleotides.
3.4.2

Sterilization

Glassware used for solution preparation were washed and cleaned by laboratory operation
unit at BioMarin. Other materials for cell culture and molecular biology were washed with
Tergazyme (Alconox), a detergent containing protease enzyme, and rinsed with tap water.
Microcentrifuge tubes placed in a cylindrical plastic container with lid were sterilized by
autoclaving at 121⁰ C for 45 minutes under a pressure of 1 bar by lab operation personnel.
3.4.3

Reconstitution of lyophilized miRNA

Lyophilized MicroRNAs were reconstituted by the addition of nuclease-free molecular water
(GE healthcare LifeSciences, SH30538.01) to a final stock concentration of 20 or 100 μM.
After the addition of nuclease-free water, mixing was done by up and down pipetting. The
mixture was allowed to incubate for 10 minutes at room temperature before being transferred
to -20⁰ C for storage.
3.4.4

Rehydration of antibodies

Primary and secondary antibodies for Western Blotting were rehydrated by the addition of
certain amount 1X DPBS to a concentration recommended by the supplier of the antibodies.
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After addition of 1X DPBS, mixing was done by up and down pipetting followed by
centrifugation at 250 x g for 30 seconds.
3.4.5

Extraction of total RNA (including small RNA - microRNA)

Total RNA, including small RNA, was extracted using Quick-RNA Microprep (Zymo Research,
R1050). Samples of suspension cells were pelleted at 250 x g for 5 minutes in a minicentrifuge
(Eppendorf) and supernatant discarded. For adherent cells, the cells were dissociated with
TrypLE Express (Thermo, 12605028) and pelleted as described above. For both adherent
and suspension cells, the cell pellets were resuspended in 200 – 400 uL of RNA lysis buffer
and vortexed briefly for homogenization. Particulates were removed by centrifuging the
lysates at 14000 x g for 1 minute. To purify the RNA, the supernatant was transferred to an
RNase-free tube and 100% ethanol added to the lysis buffer containing the sample at a ratio
of 1:1. Reaction mixture was well mixed by up and down pipetting. The mixture was
transferred to a Zymo-Spin IC column enclosed in a 2 mL collection tube and centrifuged at
14000 x g for 30 seconds. The flow-through was discarded. For trace DNA removal, the
column was washed with 400 uL of RNA wash buffer and centrifuged at 14000 x g for 30
seconds. The flow-through was discarded. DNase I reaction mixture was prepared using
DNase I and DNA digestion buffer at a ratio of 1:7 respectively. 40 uL of DNase I reaction
mixture was added into the spin column directly, incubated at room temperature for 15
minutes and then centrifuged at 14000 x g for 30 seconds. 400 uL of RNA prep buffer was
added to the column, centrifuged at 14000 x g for 30 seconds and flow-through discarded.
The column was washed with 700 uL RNA wash buffer, centrifuged at 14000 x g for 30
seconds and flow through discarded. 400 uL of wash buffer was added to the column and
spun at 14000 x g for 2 minutes to completely remove residual wash buffer in the column. The
column was transferred to a new 1.5 mL tube (Eppendorf) and 40 uL of DNase/RNase-free
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water was added into the column and centrifuged at 14000 x g for 30 seconds for RNA elution.
The eluted RNA was stored at 80⁰ C.
3.4.6

Determination of nucleic acid concentration

Quantification of double stranded DNA (dsDNA) or single stranded RNA (ssRNA)
concentration was carried out using DS-11 spectrophotometer (Denovix) by following
manufacturer’s protocol.
3.4.6.1

Plasmid DNA

The dsDNA icon was first tapped. This led to the opening of the dsDNA measurement window.
The top and bottom sample surfaces of the DS-11 spectrophotometer (Denovix) was wiped
down with a dry lab wipe and 2 uL of nuclease-free water (Qiagen) was pipetted on the sample
surface as blank measurement. The top arm was lowered and the “blank” button tapped. After
blank measurement, the sample surface was wiped down with fresh dry lab wipe. 2 uL of test
sample (dsDNA) solution was pipetted onto sample surface, sample name entered, arm
lowered and the “measure” button tapped to obtain absorbance value. The measurement
generates DNA concentration in ng/μL including the 260/280 and 260/230 absorbance values.
The result was exported through the instrument email messaging system.
3.4.6.2

Total RNA

The same protocol was followed as illustrated above for dsDNA except that RNA icon was
tapped for measurement of RNA absorbance values.
3.4.7

Determination of RNA quantity and quality using Bioanalyzer

Total RNA concentration and quality were determined on the Agilent 2100 Bioanalyzer
instrument using the RNA 6000 Nano Kit (Agilent, 5067-1511) according to the instruction of
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the manufacturer. During sample preparation, total RNA isolated was diluted to 100 ng/µL
because the quantitative range for analysis on the instrument falls between 25 – 500 ng/µL.
Before each measurement on the Agilent 2100 Bioanalyzer instrument, RNaseZAP (Ambion,
9780) and RNase-free water was used for routine decontamination and cleaning of the
electrode respectively. In preparing the gel, 550 μL of RNA gel matrix was pipetted into a spin
filter and centrifuged at 1700 x g for 10 minutes at room temperature, aliquoting 65 μL into a
microcentrifuge tube. The gel-dye matrix was prepared by equilibrating the RNA dye
concentrate to room temperature for 30 minutes. The dye was vortexed for 10 seconds, spun
down and 1 μL of the dye was added to the tube containing 65 μL aliquot of filtered gel. The
mixture was vortexed and spun in a minicentrifuge at 13000 x g for 10 minutes at room
temperature. After placing the RNA chip on the chip priming station (CPS), 9 μL of the geldye mix was pipetted into a well marked

. Ensuring that the plunger was positioned at 1

mL level, the CPS was closed, plunger pressed down until it was held by the clip and waited
for 30 seconds before releasing the clip. After 5 seconds, the plunger was pulled to the 1 mL
position. The CPS was opened and 9 µL of the gel-dye mix was pipetted into wells marked
. The unused gel-dye mix was discarded. 5 µL of RNA marker was pipetted into all 12
sample wells and in the well marked with a ladder sign. In addition, 1 µL of each RNA sample
was pipetted into the sample wells depending on the number of RNA sample being analyzed.
1 µL of the RNA marker was pipetted into each unused sample well. The chip was placed
unto an IKA vortex mixer horizontally and vortexed at 2400 rpm for 1 minute. Finally, within 5
minutes the chip was ran on the Agilent 2100 Bioanalyzer instrument to obtain the RNA
concentration and RNA integrity number (RIN). The RIN gives an estimate of the quality of
the RNA and it ranges from 1 – 10, with 10 being the best quality.
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3.4.8

Reverse transcription (cDNA generation)

Reverse transcription experiment was carried out using miScript II RT Kit (Qiagen, 218160)
for the generation of complementary DNA (cDNA) following instructions from the
manufacturer. Total RNA, containing miRNA, was used as a template. RNA sample stored in
-80⁰ C was thawed in ice, while 10X miScript Nucleic Mix and 5X miScript HiSpec Buffer were
thawed at room temperature and later placed on ice. In order to synthesize first-strand cDNA,
reverse-transcription master mix was prepared in a microcentrifuge tube for each RNA sample
by adding 4 µL HiSpec buffer, 2 µL Nucleic mix, 2 µL miScript Reverse Transcriptase Mix,
RNase-free water (amount depends on RNA template amount used) and finally RNA sample
(amount used depends on RNA sample concentration used which falls at the upper limit of 10
ng – 2 µg) for total mixture of 20 µL. The master mix was mixed gently, centrifuged and placed
on ice. The tube containing master mix was incubated in a thermal cycler (Life Technologies)
at 37⁰ C for 60 minutes, then at 95⁰ C for 5 minutes in order to inactivate miScript Reverse
Transcriptase Mix. Tube was later placed on ice. The 20 µL reaction mixture was diluted by
adding 200 µL of RNase-free water, mixed gently and centrifuged. This ensured that cDNA
generated fell between 50 pg – 3 ng per PCR. The diluted cDNA was either used immediately
for real-time PCR or the undiluted cDNA was stored at -20⁰ C for future real-time PCR
experiment.
3.4.9

Real Time-PCR (qPCR)

The real-time PCR (qPCR) was carried out using a miScript SYBR Green PCR Kit (Qiagen,
218073) with miScript Primer Assay according to the protocol of the manufacturer for the
detection of mature miRNA. All the content of each reagent: 2X QuantiTect SYBR Green PCR
Master Mix, 10X miScript Universal Reverse Primer, and diluted cDNA was thawed, mixed
and centrifuged before use. A reaction master mix was prepared according to Table 1.
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Table 3: Reaction master mix for the detection of matured miRNA in a 384-well plate

Component

Volume/reaction
(384-well)

2x QuantiTect SYBR Green PCR Master Mix

5 µL

10x miScript Universal Reverse Primer

1 µL

10x miScript Primer Assay (U6 snoRNA, GAPDH, miRNA of

1 µL

interest)
RNase-free water

2 µL

cDNA Template (not added in master mix)

1 µL

Total volume

10 µL

The GAPDH and U6 SnoRNA forward primers were used for normalization of gene expression
and mature miRNA expression levels respectively. The reaction master mix was prepared for
three technical replicates with extra 10% reaction component used to compensate for loses
due to pipetting. 1 µL of the cDNA template was dispensed into individual wells of the PCR
plate for each replicate. The reaction master mix was mixed thoroughly and 9 µL dispensed
into wells containing cDNA. The plate was tightly sealed with a film and centrifuged at 1000 x
g for 1 minute at room temperature. The real-time LightCycler 480 (Roche Diagnostics) was
programed according to the shown below. In addition, melting curve analysis was done to
verify specificity (primer-dimer).
Table 4: Roche LightCycler 480 cycling conditions

Step

Time

Temperature

Activation step

15 min

95⁰ C
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3-step cycling:
Denaturation

15 s

94⁰ C

Annealing

30 s

55⁰ C

Extension

30 s

70⁰ C

Cycle number

45 cycles

The plate was placed in the real-time cycler and program started. The C(T) method
(Schmittgen and Livak 2008) was used to calculate relative expression differences.
3.4.10

Molecular cloning

3.4.10.1 Agarose gel preparation
In order to make 500 mL of agarose gel, 5g of Seakem LE Agarose (Lonza, 50004) was
measured and poured into an amber bottle followed by the addition of 300 mL of TAE 1X
buffer. The amber bottle with mixture was heated up in a microwave for at least 2 minutes to
dissolve the agarose powder. 50 μL of 1X of Biotium gel green nucleic acid stain was added
into bottle and mixed by gentle swirling. The bottle containing freshly prepared agarose gel
was kept at 65⁰ C in a bead bath (Lab Amor).
3.4.10.2 Gel extraction
This process was carried out using the QIAquick Gel Extraction Kit (Qiagen, 28704) by
following the procedures stated by the manufacturer. DNA was purified from small piece of
gel that contained our desired DNA. Gel slice containing desired DNA was cut from agarose
gel with a scalpel and transferred into a 1.5 mL microcentrifuge tube. The gel slice was
weighed to accommodate the maximum amount (400 mg) the spin column could hold. Buffer
QG was added to the tube with gel at a volume of 3:1 (100 mg gel ~ 100 μL). Gel was
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incubated at 60⁰ C and vortexed every 2 minutes until gel slice dissolved completely. The gel
sample was transferred to a MinElute spin column placed inside a 2 mL collection tube and
centrifuged at 17900 x g for 1 minute at room temperature. The flow-through was discarded
and process repeated if sample was greater than 800 μL. 500 μL of Buffer QG was added to
the column and centrifuged at 17900 x g for 1 minute at room temperature. The flow-through
was discarded and column placed back into the collection tube. Similar process as above was
repeated using 750 μL of Buffer PE; however, the column was allowed to incubate for 3 minute
after adding Buffer PE if DNA was intended for sequencing or blunt-ended ligation
downstream. After discarding the flow-through to completely remove residual ethanol, the
column contained in 2 mL collection tube was centrifuged at 17900 x g for 1 minute at room
temperature. Column was placed in a new 1.5 mL microcentrifuge tube and 10 μL Buffer EB
added to the center of the column membrane. To elute the DNA, the column was allowed to
stand for 1 minute and centrifuged at 17900 x g for 1 minute at room temperature.
3.4.10.3 PCR purification
For the purification of PCR products, QIAquick PCR Purification Kit (Qiagen, 28104) was used
according to specifications by the manufacturer. 5 volumes of Buffer PB was added to 1
volume of the PCR reaction and mixed gently. The sample was transferred to a QIAquick
column placed in a 2 mL collection tube and centrifuged at 17900 x g for 60 seconds at room
temperature. After discarding the flow-through, 750 μL of wash Buffer PE was added and
centrifuged at 17900 x g for 60 seconds at room temperature. In order to remove residual
wash buffer, the column in 2 mL collection tube was centrifuged again for 1 minute at same
conditions. After placing the column in a new 1.5 mL microcentrifuge tube, 30 μL of Buffer EB
was added to the center of column, allowed to stand for 1 minute and centrifuged at 17900 x
g for 1 minute at room temperature in order to elute DNA.
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3.4.10.4 Plasmid DNA purification (maxiprep)
Automated maxiprep purification of plasmid DNA was carried out using the BenchPro 2100
Maxicard Plasmid Purification Instrument (Life Technologies) according to the purification
protocols of the manufacturer. The instrument and air compressor was turned on and made
sure that the air compressor wasn’t letting out air. Setup button was tapped to set up the
instrument for maxiprep purification. The reagent tray foil was pierced with a piercing tool and
an empty 2 mL collection tube with cap removed was placed into the elution tube slot. After
opening the drawer of the instrument, the waste tray was removed and reagent tray placed in
the waste tray slot ensuring the tray aligned with the slot. A cell liner was placed in the waste
tray reservoir slot. The drawer was opened and waste tray containing reagent tray was placed
into the waste tray slot. About 125 mL of E. coli culture was poured into the cell liner contained
in the reservoir and covered with a lid. The drawer was closed gently which was followed with
the insertion of the Maxiprep Card into a slot in the BenchPro 2100 instrument. The start
button was tapped, following by the click of the run button in order to run the protocol. At the
completion of the run, the card was removed from the slot and discarded. The drawer unit
was opened to remove the elution tube containing purified plasmid DNA. The tube was
capped and stored at -20⁰ C. The reagent tray and cell liner were discarded appropriately and
the waste tray decontaminated with bleach and washed with detergent for future use.
3.4.10.5 Transformation
2 µL ligation reaction was added into vial containing One Shot TOP10 chemically competent
E. coli and gently mixed. This was incubated on ice for 20 minutes. The cells in the vial was
heat-shocked at 42⁰ C for 30 seconds and transferred immediately to ice. 250 µL of super
optimal broth with catabolite repression (S.O.C) medium kept at room temperature was added
into each vial and incubated at 37⁰ C for 1 hour with shaking. Depending on the size of the
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plasmid, 20 – 100 µL of bacterial culture was dropped using a pipette close to the edge of the
LB agar plate containing 50 µg/mL spectinomycin. An inoculation loop was used to streak the
dropped bacteria culture on the LB agar plate in a clockwise manner. The plate was incubated
overnight at 37⁰ C.
3.4.10.6 Purification of plasmid DNA (miniprep)
QuickLyse Miniprep Kit (Qiagen, 27505) was used by following the protocols of the
manufacturer. It was ensured that the OD600 of E. coli cells from 2 mL culture fell between 1.8
– 2.2 using a nano-spectrophotometer (Denovix). If it is greater than 2.2, the culture was
diluted to 2.0 with deionized DNA-free water. 1.5 mL of the bacteria culture was pipetted into
2 mL QuickLyse Lysis Tube and centrifuged at 18000 x g for 1 minute at room temperature.
The supernatant was decanted by inverting the tube on a paper towel. 400 µL of ice-cold
Complete Lysis Solution (placed on ice) was added to bacteria pellet and vortexed at the
highest setting for 30 seconds. The vortexing was continued until cell clumps were completely
resuspended. The lysate was incubated at room temperature for 3 minutes and pipetted into
a QuickLyse spin column. The spin column was centrifuged at 17000 x g for 60 seconds. The
flow-through was decanted and spin column placed back into tube. The spin column was
washed by adding 400 µL of Buffer QLW and centrifuged at 17000 x g for 60 seconds. The
flow-through was discarded. The spin column was placed in a new waste tube and centrifuged
at 17000 x g for 1 minute to dry the spin column. After transferring the spin column into a new
1.5 mL microcentrifuge tube, 50 µL Buffer QLE was pipetted into the center of the spin column
to elute DNA by centrifuging at 17000 x g for 60 seconds.
2.4.10.7 Restriction endonuclease digest
Restriction enzyme digest carried out was adapted from protocol recommended by New
England BioLabs (NEB). The purpose of the experiment was to confirm the quality (clean
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bands and right sizes) of the plasmid purified using the miniprep (Qiagen). Total reaction
volume was 50 µL for digestion of 1 µg of substrate. In order to identify the right enzyme for
digestion, the plasmid vector map was viewed on Snapgene software. After identifying at least
two enzymes, 10U of each enzyme was used for digestion without exceeding 10% of total
reaction volume (50 µL). Typically, after determining the right volume to be used for each
reagent, HyPure deionized water (GE Healthcare) was first added into a PCR tube to make
up the remaining difference of the 50 µL of total reaction volume. Next, 5 µL of Cutsmart buffer
(NEB) was added into the PCR tube. The type of buffer used depended on the enzyme used.
The enzymes are better suited to different buffers. This was followed by the addition of 1 µg
of the plasmid DNA and the right volume of enzymes were added lastly. The PCR tube
containing reaction volume was incubated in Veriti 96-well thermal cycler (Applied
Biosystems) at 37⁰ C for 1 hour. While the reaction was incubating, 1% agarose gel was
poured into an electrophoresis chamber which was allowed to solidify for about 20 - 30
minutes. 1X TAE buffer was poured into the electrophoresis chamber containing agarose gel
to a point a little above the gel level. After the samples have finished incubating, 10 µL of 6X
gel loading dye (New England BioLabs, B7024S) was added to all the samples. 15 µL of each
sample were loaded into each lane and 10 µL DNA ladder (ThermoFisher, SM0312) in one
lane. The gel was ran for about 45 minutes – 1 hour at 100V. At the end, the gel was imaged
(Azure Biosystems, c200) and compared to the predicted image as depicted by the Snapgene
software gel electrophoresis predictive tool when simulated with the restriction enzymes used.
3.4.10.8 BigDye® Polymerase Chain Reaction (PCR) cycle sequencing
Purified DNA plasmid was amplified using BigDye® cycle sequencing (Applied Biosystems)
protocol as recommended by the manufacturer. The table below shows the amount of reagent
added for each reaction in a microcentrifuge tube.
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Table 5: BigDye reaction mix preparation

Reagent

Quantity

1. BigDye ready reaction mix

8 µL

2. Plasmid DNA template (500 – 1000 ng)

2 µL

3. Primer @ 3.2 pmol/ µL (Forward & Reverse) 1 µL
4. Deionized water

9 µL

Total volume

20 µL

Each reaction was carried out separately for the forward and reverse primer of the DNA
template. After adding all reagents in the order listed in Table 3, each tube was mixed well
and spun briefly. The tubes were placed in Veriti thermal cycler (Applied Biosystems), volume
of reaction set to 20 µL and PCR cycle parameters entered as seen in Table 4 below and
PCR reaction started.
Table 6: BigDye PCR reaction parameters

96⁰ C

1 min

1 cycle

96⁰ C

10 sec

50⁰ C (depending on template primer)

5 sec

60⁰ C

4 min

25 cycles

4⁰ C

∞

hold

3.4.10.9 DNA sequencing clean-up
This process was carried out using ZR DNA sequencing clean-up kit (Zymo Research, D4050)
according to the protocol of the manufacturer. 240 µL of sequencing binding buffer was added
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to the 20 µL PCR sequencing reaction sample and mixed. The mixture was transferred into
Zymo-Spin IB Column in a collection tube. The spin column with collection tube was
centrifuged at 10000 rpm for 1 minute. 300 µL of wash buffer was added to the column and
centrifuged at 10000 rpm for 1 minute. Spin column was placed into a new 1.5 mL
microcentrifuge tube. 20 µL of Hi-Di formamide solution was added into the column and
centrifuged at 10000 rpm for 1 minute. The eluted PCR product was transferred to a clean
Axygen 96-well sequencing plate for subsequent use with the sequencing instrument.
3.5

PROTEIN ANALYSIS

3.5.1

Bicinchoninic acid (BCA) Protein Assay (microplate procedure)

A stock of the diluted standards (Bovine serum albumin-BSA) was prepared in clean
Eppendorf tubes with concentration ranging from 2000 µg/mL to 25 µg/mL and using the
diluent (distilled water) as blank. The cell lysate to be tested was diluted to bring total protein
concentration to between 2000 ug/mL and 25 ug/mL based on historical or previous
experience with cell type and cell culture condition. 10 uL of each standard and sample in
duplicates were added to the corner of the well in a clear 96-well plate (Corning, 3641). Finally,
200 uL of the working reagent (WR) was added into all wells and mixed well by up and down
pipetting. The microplate was transferred to a Jitterbug (Boekel Scientific, 130000-115V), a
heated microplate shaker, mixed for 10 minutes and incubated at 37⁰ C for 30 minutes.
Thereafter, absorbance reading was measured at 562nm on a SoftMax plate reader.
3.5.2

Western Blot (Immunoblotting)

The harvested cells were pelleted by centrifugation (Eppendorf, centrifuge 5424) at 2500 rcf
for 10 minutes and supernatant discarded. MPER Mammalian Protein Extraction Reagent Kit
(Thermofisher, 78501) and Halt Protease Inhibitor cocktail (Thermo Scientific, 87785) were

32

DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD

mixed at a ratio of 100:1 respectively. A certain amount of volume (depending on the cell
density) of the mixture, between 100 – 400 uL was added to the pelleted cells. This was mixed
by pipetting up and down. The mixture was shaken gently for about 10 minutes and
centrifuged at 14000 rcf for 15 minutes to remove cell debris. Supernatants were transferred
into a new 1.5 mL microcentrifuge tube (Eppendorf) for storage at 80⁰ C or used immediately
for sample preparation. The samples were prepared with a mix of sample buffer, reducing
agent and distilled water using manufacturer protocol. The samples were then heated to 95⁰ C
in a microcentrifuge heating block (VWR) for 10 minutes. Samples were loaded into wells in
a 4 - 12% SDS-polyacrylamide gel Nupage premade gels (Novex, Invitrogen by Thermo
Scientific) containing 1X MOPS SDS running buffer (Novel by Life Technologies, NP0001).
10 uL of SeeBluePlus2 pre-stained protein ladder (Thermo Scientific, LC5925) was used as
a molecular weight standard. Required volume of samples depending on gel size used was
added to the remaining wells. Gel was ran in a PowerPac 200/300 electrophoresis power
supply (Biorad) at 100V for 5-10 minutes, then increased to 110V after samples were out of
the wells and into the stacking gel. Samples were allowed to run until they get to the bottom
of the gel. The stacked gel casing was rinsed with deionized water. Proteins were transferred
from the gel to a nitrocellulose membrane using the iBlot 2 dry blotting system (Life
Technologies) with iBlot 2 transfer stacks (Invitrogen, IB23002). The membranes were
allowed to wash in a blocking buffer (Thermo Scientific, 37543) for 1 hour on a shaker at room
temperature. The following primary antibodies: human SUMF1 (1:1000 #TA337720 Origene),
mouse/human SUMF1 (1:500 #MAB2779 R&D Systems), GAPDH (1:5000 #PA1-988 Thermo
Scientific), were diluted in blocking buffer and used to probe the membrane overnight at 4⁰ C
on a shaker. Next, the membranes were probed with fluorochrome-conjugated secondary
antibodies and detected with Odyssey CLx Imaging System (LICOR Biosciences) after 1 hour
of incubation.
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CHAPTER 4

mRNA and miRNA profiling of a high and low CHO cell producer clones stably
expressing a difficult-to-express lysosomal protein using next generation
sequencing

Ifeanyi Michael Amadi1, 2, Kevin Ru1, Vishal Agrawal1, Terri Christianson1,
Karen Yu1, Cameron Bardliving2, Parviz Shamlou2, Jonathan Lebowitz1
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BioMarin Pharmaceutical Inc. 105 Digital Dr. Novato, California 94949, USA
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ABSTRACT
Chinese hamster ovary (CHO) cells have become the workhorse for the manufacturing of
recombinant therapeutic protein and the use of a fed-batch biphasic (temperature shift at
the early part of cell growth) process have tremendously improved the volumetric yield of
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most well understood therapeutic proteins. However, difficult-to-express (DTE) recombinant
therapeutic protein like complex multi-specific proteins, DTE mAbs, and lysosomal enzymes
have seen difficulties in manufacturability of CHO cells and other mammalian cells as
production platforms. In addition, genetic heterogeneity and clonal variations in CHO cell
lines have been shown to produce cells with variable cellular growth rate, product yield and
specific productivity. In this study, we sought to understand the gene and miRNA expression
profile dynamics of three in-house CHO cell lines (non-producer, low and high producers)
stably secreting a DTE lysosomal protein but differ in their growth rate, specific productivity
and titer. MicroRNA are short non-coding RNA with 18-24 nucleotide in length. They have
been shown to play major roles in various cellular processes with relevance and impact in
bioprocessing phenotypes. Next-generation sequencing (NGS) technology was employed
for mRNA and miRNA expression analysis of samples taken on day 3, 5, 7 and 10 from
CHO cells grown in a 5L fed-batch biphasic bioreactor. The RNA-Seq and small RNA-Seq
data were analyzed by the Bioinformatics group at BioMarin. Correlation and differential
analyses from the analyzed data identified 500 mRNAs and 35 miRNAs that were
differentially expressed (DE) in the in-house CHO cell lines over cultivation period.
Meanwhile, from the 35 DE miRNAs, cgr-miR-31-5p represent the top DE miRNA with an
upregulation of 131 fold in the higher producer compared to the lower producer. In addition,
correlation results of mRNA and miRNA expression profile were also determined. Taken
together, this study has been able to provide miRNA and mRNA expression dynamic
changes in CHO clones that differ in growth and productivity profiles, while providing
potential targets for CHO cell engineering for desirable bioprocess phenotype.

Keywords: Chinese hamster ovary (CHO cells), cell engineering, microRNA (miRNA),
lysosomal protein, Next generation sequencing (NGS), difficult-to-express (DTE)
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Abbreviations: CHO, Chinese hamster ovary; DTE, difficult-to-express; miRNA,
microRNA; UTR; qRT-PCR, real-time quantitative reverse-transcription PCR; CHO-lys,
CHO cell secreting lysosomal protein
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4.0

Introduction

Among mammalian cells used for recombinant therapeutic production, CHO cell has
remained the dominant player as most approved biologics were manufactured in CHO cells.
Moreover, tremendous efforts by scientists have helped in pushing the productive capacity
of CHO cells to a much higher volumetric yield via media optimization (Buchsteiner et al.
2018; Clincke et al. 2011), cellular (Dorai et al. 2010; Druz et al. 2013), process (Gagnon et
al. 2011) and genetic engineering (Rajendra, Peery, and Barnard 2016; Jazayeri et al.
2018). However, the latter approach entails the manipulation of gene expression which
could add an extra translational burden on the host cell (Migani, Smales, and Bracewell,
2017). Recently, microRNA-engineering of CHO cells have shown proven efficacy at
improving cell specific productivity (Fischer, Paul, et al. 2015; Kelly et al. 2015; Meyer et al.
2017; Emmerling et al. 2016; Loh et al. 2014), growth rate (Strotbek et al. 2013), and
apoptosis resistance (Druz et al. 2013) in CHO cell lines expressing less complex and well
understood recombinant therapeutic proteins.
MicroRNA (miRNA) are small (18-24 nucleotide) non-coding RNA with the ability to regulate
~30% of gene expression in cells post-transcriptionally (Pasquinelli 2012; Bratkovič et al.
2012; Winter et al. 2009; Ha and Kim 2014). The pleiotropic function of most miRNA allows
one miRNA to target more than one mRNA transcripts (Fischer, Handrick, et al. 2015).
MiRNA transcription begins at the nucleus and is transcribed by RNA polymerase II into a
long primary transcript (pri-miRNA) with multiple stem loops. Thereafter, the pri-miRNA is
processed in the nucleus by microprocessors (Drosha and DGCR8) into a hairpin structure
(~72 nt long) called precursor miRNA (pre-miRNA) and exported via exportin-5 (XPO5) into
the cytoplasm in a RanGTP-dependent manner.

While in the cytoplasm, Dicer, an

endoribonuclease, trims the stem loop of the pre-miRNA forming a miRNA duplex (~22 nt)
which consist of 5p or 3p mature strands. Either the 5p or 3p strand is selected (the other is
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either degraded, but not in all cases) for attachment with Argonaute protein family to form a
complex called miRNA-induced silencing complex (miRISC). The miRNA directs the
miRISC to a potential mRNA transcript target for inactivation via translational repression,
deadenylation or degradation (O’Brien et al. 2018; Pasquinelli 2012). A couple of studies
have used next generation sequencing (NGS) (Hackl et al. 2011; Stiefel et al. 2016; Monger
et al. 2015; Hammond et al. 2012), microarray technology (Maccani et al. 2014; Klanert et
al. 2016; Bort et al. 2012; Harreither et al. 2015), mass spectrometry (Clarke et al. 2012;
Meleady et al. 2011) and microRNA library (Strotbek et al. 2013) to profile the transcriptome
(miRNA and/or mRNA) or proteome in CHO cells cultivated either in batch (Clarke et al.
2012; Bort et al. 2012; Harreither et al. 2015), fed-batch (Stiefel et al. 2016; Klanert et al.
2016; Meleady et al. 2011), steady-state mode (Maccani et al. 2014) or in adherent cell
culture (Hammond et al. 2012; Hackl et al. 2011). However, only few of these studies have
used CHO cell lines secreting a difficult-to-express (DTE) protein. Studies that have
evaluated mRNA and/or miRNA expression profile changes in CHO cells secreting DTE
protein (e.g. EPO-Fc fusion protein) either used microarray technology for analysis or
steady-state cultivation of the CHO cell lines (Maccani et al. 2014; Klanert et al. 2016);
microarray technology doesn’t have the high sensitivity of NGS for low (or rare) and high
gene abundance (Hurd and Nelson 2009) just as steady-state cultivation may not give a
true picture of miRNA expression changes as in a traditional fed-batch process commonly
used in the industry. Currently, few works have be done testing the limit of miRNAengineering of CHO cells secreting DTE proteins such as complex multi-specific proteins,
DTE mAbs. However, most DTE proteins like lysosomal enzymes have seen difficulties in
manufacturability using CHO cells or other mammalian cells as production platforms
(Migani, Smales, and Bracewell 2017; Liu et al. 2017).
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In this study, we sought to understand transcriptional (mRNA and miRNA) expression
changes in CHO cell lines (CHO-lys-low producer, CHO-lys-high producer, and CHO-nonproducer) secreting a DTE lysosomal enzyme and cultivated in a fed-batch biphasic mode
within a 5L bioreactor. 500 DE mRNA (FDR<0.05 & FC>2 or <0.5) and 35 DE miRNA
(FDR<0.05) were identified. Among the 35 DE miRNAs, cgr-miR-31-5p was found to be 131
fold upregulated in CHO-lys-high producer compared to CHO-lys-low producer. In addition,
miRNA associated with growth rate and titer were also determined.

4.1

Materials and Methods

4.1.1

Cell lines and cell culture

CHO suspension cell line (CHO-non-producer) and two other in house producer cell lines
derived as clones from the CHO-non-producer stably express a lysosomal protein and were
cultivated in CD CHO medium (Thermo Scientific, Waltham, MA, USA), but supplemented
with 8 mM GlutaMax (Thermo Scientific, Waltham, MA, USA) for CHO-non-producer only.
The producer cell lines differ by their specific productivity (also in titer and growth rate), so
are identified as low and higher producer relative to their production capacity. The high
producer (CHO-lys-high) have a specific productivity and titer that is 3x and 2x higher
respectively compared to the low producer (CHO-lys-low). However, CHO-lys-low shows a
growth rate that is 2x that of the CHO-lys-high producer. Inoculation cells were sourced from
cells maintained with a working volume of 30-150 mL within a shake flask (Corning,
Oneonta, NY, USA) at 37⁰C, 5% CO2 and 80% humidity in an orbital shaker incubator
(Infors HT, Annapolis Junction, Maryland, USA) agitated at 125 rpm. Cells were passaged
every 3-4 days at a seeding density of 0.5 x 106 cells/mL. Cell concentration and viability
were measured using the ViCellTM (Beckman Coulter, Brea, CA, USA) by the trypan blue
exclusion method. For functional validation study of target miRNAs, CHO suspension cells
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were cultivated in CD CHO medium ((Thermo Scientific, Waltham, MA, USA) at a seeding
density of 0.9-1 x 106 cells/mL and propagated in a 6-well plate for 72 hours (Life
Technologies, Grand Island, New York). Culture was maintained at 37⁰ C, 5% CO2 and
80% humidity in a static incubator (Thermo Scientific, Waltham, MA, USA) and samples
taken at 48 h and 72 h for RNA isolation and protein concentration/western blotting analysis
respectively.

4.1.2 Bioreactor fed-batch cultivation
CHO-non-producer, CHO-lys-low, and CHO-lys-high producer cell lines were cultivated in
5L Dasgip bioreactors in a biphasic (temperature shift on D5, from 37⁰C to 30⁰C) fed-batch
mode. The bioreactors were inoculated at a seeding density of ~0.4 x 106 cells/mL with a
working volume of 3L and cultivated for 14 days. The cells were cultured in a CD CHO
medium (Thermo Scientific, Waltham, MA, USA) and maintained at 37⁰C, pH 6.9 (Figure
3D), dissolved oxygen 30% and 80 rpm agitation. On day 3 and 5, 5% and 10% efficient
feed B media was added respectively. In addition, to maintain adequate supply of energy
source for cells to growth and synthesize products, glucose levels were maintained at 2 g/L.
Moreover, offline monitoring of cell health, substrate, and metabolic concentrations were
measured using the ViCellTM (Beckman Coulter, Brea, CA, USA) by the trypan blue
exclusion method for cell concentration and viability, while the Bioprofile Flex Analyzer
(Nova Biomedical, Waltham, MA, USA) was used for glucose, lactate, glutamine, and
glutamate concentration measurements.
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4.1.3 Transient transfection of mimics and inhibitors
Transient transfection of miRNA mimics (mmu-miR-31-5p) and inhibitors (anti-mmu-miR31-5p) (Qiagen, Germantown, MD, USA; Dharmacon, GE Healthcare, Lafayette, CO, USA)
were carried out using LipofectamineTM RNAiMax (Thermo Scientific, Waltham, MA, USA)
transfection reagent and Opti-MEM I (Thermo Scientific, Waltham, MA, USA) reduced
serum medium for complex formation at a final concentration of 50 nM, unless indicated
differently. The scramble universal negative control (Sigma-Aldrich, Louis, MO, USA) was
used as a non-targeting control (NT-siRNA).

4.1.4 Real-time Quantitative Reverse-Transcription PCR (qRT-PCR)
Briefly, cDNA was synthesized from 1 μg of total RNA using miScript II kit (Qiagen,
Germantown, MD, USA) for quantification of mature miRNA(s) expression and Superscript
Vilo kit (Invitrogen, Thermo Scientific, Carlsbad, CA, USA) for gene expression
quantification according to the protocol of the manufacturers. For the quantification of
matured miRNAs and gene expression, qRT-PCR was performed with 10-1 diluted cDNA on
a LightCycler 480 (Roche Molecular Diagnostics, Pleasanton, CA, USA) using Ssofast TM
Evagreen® Supermix (BioRad, Hercules, CA, USA) according to the protocols of the
manufacturer. GAPDH and U6 snoRNA were used for the normalization of gene expression
and mature miRNA expression levels respectively. miScript Universal Reverse Primer
(Qiagen, Germantown, MD, USA) was used for mature miRNA analysis. Details of primers
used for qRT-PCR (Table 14). For the quantification of relative gene expression, the
comparative C (T) method was employed.
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4.1.5 Western blot analysis
Protein extraction on harvested cells was done using the M-PER mammalian Protein
Extraction Reagent Kit (Thermo Scientific, Carlsbad, CA, USA) according to the protocol of
the manufacturer. Halt Protease Inhibitor Cocktail (Thermo Scientific, Carlsbad, CA, USA)
was mixed with the extraction solution at a ratio of 1:100 respectively. Total protein was
determined using the bicinchoninic acid (BCA) protein assay (Thermo Scientific, Carlsbad,
CA, USA) according to the protocol of the manufacturer. Cellular proteins were separated
in a 4-12% SDS-polyacrylamide Nupage premade gels (Thermo Scientific) using a 1X
MOPS SDS running buffer. Proteins were transferred from the gel to a nitrocellulose
membrane using the iBlot 2 dry blotting system (Life Technologies). The membranes were
allowed to wash in a blocking buffer (Thermo Scientific) for 1 hour on a shaker at room
temperature. The primary antibody against the secreted lysosomal protein was in house and
sourced in bulk from a biotech company. The other primary antibody used was GAPDH
(1:5000, PA1-988, Thermo Scientific). All primary antibodies were diluted in blocking buffer
and used to probe membrane overnight at 4⁰ C on a shaker. Thereafter, the membranes
were probed with fluorochrome-conjugated secondary antibodies (LICOR Biosciences,
Lincoln, Nebraska, USA) and detected with Odyssey CLx Imaging System (LICOR
Biosciences, Lincoln, Nebraska, USA) after 1 hour of incubation.

4.1.6 Enzymatic assay (titer)
For determination of titer values from sample supernatants, 4-MUGAL was used as
substrate and carried out in a 96-well plate format. All standard and in-house control
samples were diluted to appropriate concentrations. Substrate mixture were loaded into
plate wells, and incubated at 37⁰C for 40 minutes. Fluorescence was read at 325 nm
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(excitation) and 420 nm (emission) on a SpectraMax M3 plate reader (Molecular Devices,
San Jose, CA, USA)

4.1.7 Bioinformatics analyses
To determine the differential expression of global gene and miRNA expression profiles in
the lower producer (CHO-lys-low), higher producer (CHO-lys-high) and parental cell line
(CHO-non-producer) and their correlation with relevant bioprocess phenotypes (e.g. growth,
titer) samples were taken on day 3, 5, 7, and 10 and processed using next generation
sequencing (NGS) by an external company. The RNA-seq and small RNA-seq data
analyses was performed by the Bioinformatics group at BioMarin. For NGS, the parameters
used can be found in Table 7. The prospective target genes (integration of predicted and
gene target from RNA-seq data) of the 35 DE miRNAs were obtained from the results of the
RNA-seq data analyses. Functional annotation of predicted genes was analyzed using
Database for Annotation, Visualization and Integrated Discovery (DAVID) online tool
(https://david.ncifcrf.gov/).

4.2

Results

4.2.1 Fed-batch cell culture cultivation
Three CHO cell lines were cultivated in a biphasic fed-batch process using 5L Dasgip
bioreactors in quadruplicate for each cell line. One of the cell lines is CHO-parental (CHOnon-producer) and the other two are CHO-lys-low and CHO-lys-high producers derived as
clones from the parental cell secreting a difficult-to-express (DTE) lysosomal enzyme. CHOlys-low and CHO-lys-high producer clones were classified as low and high producers
respectively based on their relative differences in volumetric and specific productivity (Table
8). Although, CHO-lys-low has a better growth rate than CHO-lys-high (Figure 2A). To

43

DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD

maintain adequate energy source for the growth of the cells, glucose levels was maintained
at 2 g/L (Figure 3C) after temperature shift to 30⁰C on day 5. As the common process in
bioprocessing, the bioreactor temperature reduction to 30⁰C induced a reduction in cell
growth from day 6 (Figure 2A-B) but an increase in overall cell specific productivity (qP)
and higher viability maintenance (Figure 2C). CHO-lys-high showed a qP that is about
three times 3-fold (1.47-2.88 pg/cell/day) higher than that of CHO-lys-low producer (0.541.01 pg/cell/day) (Figure 3A). In addition, CHO-lys-high showed a titer that is about 2 fold
(~262 mg/mL) higher than that of CHO-lys-low producer expressing a final mean titer of
~154 mg/mL after day 14 harvest (Figure 3B). Based on the productivity differences
between the two clones we sought to understand the gene and microRNA profiles changes
between these clones, including the parental cell line.

4.2.2 Identification of growth-correlating miRNAs and mRNAs
To link the expression profile of genes and miRNAs to relevant bioprocess phenotype like
growth rate and titer, correlation analyses were done by the Bioinfomatics group at
BioMarin. The LogFC and FDR<0.05 of the miRNAs and mRNAs were applied for
correlation with growth rate. In total, the number of DE genes that were correlated with
growth rate in CHO-non-producer, CHO-lys-low producer and CHO-lys-high producer were
6964, 8637, and 8945 respectively. Furthermore, by overlapping all three cell lines for
identification of growth-associated genes, 529 positively correlated and 758 negatively
correlated genes were uniquely identified in the CHO-lys-high producer cell line. For
miRNAs associated with growth rate in the CHO-non-producer, CHO-lys-low producer and
CHO-lys-high producer, 62, 81 and 37 miRNAs were identified. By overlapping these three
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cell lines, 8 miRNAs (2 positively correlated and 6 negatively correlated) (Table 9)
associated with growth were uniquely identified in CHO-lys-high producer.

4.2.3 Identification of titer-correlating miRNAs and mRNAs
Likewise, as described above, miRNAs and mRNAs with association to titer in both CHOlys-low and CHO-lys-high producers were determined. Overall, 8062 DE genes in CHO-lyslow and 8093 DE genes in CHO-lys-high were determined to be associated with titer. In
addition, 1021 positively correlated and 668 negatively correlated genes were uniquely
identified in the CHO-lys-high producer cell line. Moreover, 88 and 56 miRNAs were
identified to be associated with titer in CHO-lys-low and CHO-lys-high producer cell lines
respectively. Overlapping the CHO-lys-low and CHO-lys-high producers, 17 positive
correlated miRNAs and 5 negative correlated miRNAs were identified to be uniquely
associated with CHO-lys-high producer (Table 10). Validated targets of these 17 positively
correlated miRNAs could be seen in Table 15.

4.2.4 Functional confirmation of miRNA expression by qRT-PCR
To confirm NGS results, we conducted qRT-PCR on selected 14 DE (FDR<0.05 & FC>2 or
<0.5) miRNAs derived from the 35 DE (FDR<0.05) miRNAs when CHO-lys-low producer
was compared to CHO-lys-high producer cell line. The RNA samples tested were taken from
day 7 after temperature shift on day 5 for each replicate bioreactors and we confirmed that
the expression of the miRNAs selected across the different cell lines do not overlap on this
day. Surprisingly, we could only confirm a 15-fold (131 fold From NGS result) increase of
cgr-miR-31-5p expression in CHO-lys-high producer compared to CHO-lys-low (Figure 4AJ). Though we observed a 2.43 fold increase in cgr-miR-221-5p expression in CHO-lys-high
using qRT-PCR, the result was in contrast to the one fold decrease observed from the NGS

45

DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD

result. In general, we could confirm the upregulation cgr-miR-31-5p expression in CHO-lyshigh producer compared to CHO-lys-low producer.

4.2.5 Functional effect of miR-31-5p on the secreted lysosomal protein of CHO-lyslow and CHO-lys-high producers
Since we observed a 15 fold (qRT-PCR) increase in cgr-miR-31-5p expression in CHO-lyshigh producer compared to CHO-lys-low producer, we transiently transfected both cell lines
with mmu-miR-31-5p mimics and inhibitors and cultured for 72 h in a static condition. In
addition, miR-31-5p overexpression and downregulation were confirmed after 48 h (Figure
5A-B). After 72 h of post-transfection using the mimics and inhibitors, we observed no
significant changes in cell viability and growth profile in the transfected cells compared to
the non-targeting control (si-NTC) (Figure 6A-B). Surprisingly, overexpression of mmu-miR31-5p in CHO-lys-high producer significantly increased the titer of the secreted lysosomal
protein compared to the scramble (non-targeting control) while downregulation of mmu-miR31-5p had no significant effect (Figure 6E). In contrast, overexpression of mmu-miR-31-5p
decreased the titer of the secreted lysosomal protein of the CHO-lys-low producer (Figure
6D) and an opposite effect was observed when mmu-miR-31-5p expression was
downregulated. (Figure 6C).

4.2.6 Identification of miR-31-5p target genes and functional annotation
To identify the target genes of miR-31-5p, we used DAVID in silico tool for gene ontology
(GO) functional cluster analysis. This help identify pathways that are associated with a gene
or group of genes. This analysis was conducted by using the list of miR-31-5p target genes
(integration of predicted (by atleast 3 miRNA predictive tool) and NGS DE gene lists).
Moreover, a mouse gene over a mouse genome function in the DAVID tool was used for
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the analyses since using a CHO genome background wasn’t comprehensive enough for the
number of genes tested. Only the annotated clustered groups (~#12) with adj.P.Val<0.2
(Benjamini or FDR) were selected for downstream analysis (Figure 7A). Genes related to
protein binding, endoplasmic reticulum, cytoplasm and membrane were highly expressed.
However, we went ahead to streamline the target genes into 9 potential targets by selecting
genes with relevant effect on bioprocess phenotypes and those identified in any of the 12
clustered groups by at least twice. These target genes could be tested for possible functional
studies to examine the effect of miR-31-5p on the target genes and protein expressions
(Table 11 & 12). Furthermore, the expression of the selected genes have been shown in
different studies to have an effect on protein production, protein trafficking, and cell
proliferation (Table 13).

4.3

Discussion

Different studies have evaluated the impact of miRNA and/or mRNA expression profile
dynamics on relevant bioprocess phenotypes of CHO cells (Harreither et al 2015; Monger
et al. 2015; Clarke et al. 2012; Bort et al. 2012; Klanert et al. 2016; Stiefel et al. 2016;
Maccani et al. 2014). Moreover, technologies like next-generation sequencing (NGS),
microarray and mass spectrometry have been used singly or in combination for standalone
or integrated analysis of mRNA, miRNA or protein profiles of CHO cells secreting proteins
such as mAb, SEAP, Epo-Fc. Moreover, much of these studies have indicated that global
miRNA expression profiles is either product and/or clone specific (Stiefel et al. 2016;
Maccani et al. 2014). In addition, CHO cell lines expressing well understood recombinant
protein were mostly used, which might not be indicative when comparing miRNA profile
dynamics in CHO cell lines secreting difficult-to-express (DTE) lysosomal enzymes. Studies
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that have evaluated miRNA global expression changes in CHO cells secreting DTE protein
(e.g. EPO-Fc fusion protein) either used microarray technology for analysis or steady-state
cultivation of the CHO cell lines (Maccani et al. 2014; Klanert et al. 2016); microarray
technology doesn’t have the high sensitivity of NGS for low (or rare) and high gene
abundance (Hurd and Nelson 2009) just as steady-state cultivation may not give a true
picture of miRNA expression changes as in a traditional fed-batch process. In this study, we
sought to understand miRNA/mRNA expression changes in CHO cell lines (CHO-lys-low
producer, CHO-lys-high producer, CHO-non-producer) secreting a DTE lysosomal protein.
Furthermore, CHO-lys-low producer exhibited a 2 fold increase in growth rate compare to
CHO-lys-high producer from the lag phase up to the exponential phase during cell culture
cultivation (Figure 2A). In the production of therapeutic protein this phenomenon holds true
because the increase in protein synthesis has been seen to be inversely proportional to cell
growth (Loh et al. 2014). The lower growth rate of CHO-lys-high producer may be
compensated with a higher productivity since most of the cells machineries are geared
towards protein synthesis (Lee et al. 1998). The productivity difference between the low and
high producer clones may be due to differences in their mRNA transcript levels, miRNA
expression differences or differences in the site of integration of the transgene. We
conducted a qRT-PCR experiment to ascertain the mRNA levels of the lysosomal protein
secreted by these cell lines and found that there was no significant differences between the
two clones at the transcript level (Figure 7B). In addition, clonal variation or CHO cell
genetic heterogeneity could also a play a role in the differences between the productivity
yields of these clones (Scarcelli et al. 2018; Derouazi et al. 2006). In order to develop a
meaningful and reproducible results, these cell lines were grown in a 5L Dasgip bioreactor
and cultivated for 14 days under a fed-batch biphasic (temperature shift on day 5) condition
and samples were taken on day 3, 5, 7 and 10 for RNA-seq and small RNA-seq (miRNA)

48

DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD

processing. To understand the global mRNA and miRNA profile differences between CHOlys-low and CHO-lys-high producers, we identified 500 DE mRNA (FDR<0.05 & FC>2 or
<0.5) and 35 DE miRNA (FDR<0.05).
Among the 35 DE miRNAs, cgr-miR-31-5p was found to be 131 fold upregulated in CHOlys-high producer compared to CHO-lys-low producer by taking the mean fold change at
four different time points (day 3, 5, 7, & 10) during cultivation. The high expression profile of
miR-31-5p in CHO-lys-high producer could explain its high pro-productive nature and/or
high volumetric yield relative to the CHO-lys-low producer. Joon-Ho Cho et al. were able to
show that the upregulation of miR-31 by histone deacetylase inhibitor (HDACi) caused an
induction of cellular senescence in cancer cells (Cho, Dimri, and Dimri 2015). This could
explain the 2 fold difference in growth rate between CHO-lys-high and CHO-lys-low
producers. However, from the growth correlating result, miR-31 was positively correlated
with growth (but not unique to only CHO-lys-high, also found in CHO-non-producer but not
in CHO-lys-low) and negatively correlated with titer (Table 9 & 10). This could indicate the
pleiotropic nature of miRNAs expression in different environmental conditions (Fischer,
Handrick, et al. 2015).
Looking at the DE miRNAs associated with growth (data not shown), we observed that there
were more DE miRNAs in the CHO-non-producer and CHO-lys-producer than in CHO-high
producer. This observation is in contrast with the result by Maccani et al (2014) in which
they observed much increase in mature miRNAs expression profiles in producer cell lines
(Maccani et al. 2014). Interestingly, most of the upregulated miRNAs (e.g. miR-409-3p, let7f) have been shown to cause a reduction in cellular proliferation when overexpressed. This
is could be indicative why CHO-lys-high producer exhibited a growth rate that is 2 fold lesser
compared to CHO-lys-low. Taken together, we have been able to profile the mRNA and
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miRNA expression in CHO cell lines that differ in their productivity and in addition identified
potential miRNAs as targets for CHO cell engineering.
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Sample type
library
Profiling Platform
Read length
Data output

RNA-deq

small RNA-seq

suspension cells
48
illumina HiSeq 4000
Paired-end 100 bp
30 million reads per sample

suspension cells
48
illumina HiSeq 4000
Single-end 50 bp
10 million reads per sample

Table 8: Relevant bioprocess characteristics of CHO cell lines used for cell culture in 5L bioreactor

CHO-lys-low

CHO-lys-high

CHO-non-producer

Growth

2x

X

2x

Specific
productivity

X

3.0x
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Titer

x

1.8x

Table 9: Growth correlating DE miRNAs unique to CHO-lys-high producer

Positively correlation Negative correlation
cgr-let-7d-3p
novel-mir-5393
cgr-miR-15b-5p
cgr-miR-486-5p
cgr-miR-212
novel-mir-12388
novel-mir-10785
novel-mir-13139
Table 10: Titer correlating DE miRNAs unique to CHO-lys-high producer

Positively correlation
cgr-miR-10b-5p
cgr-miR-146b-5p
cgr-miR-409-3p
cgr-miR-32-5p
cgr-let-7f
cgr-miR-486-5p
cgr-miR-192
novel-mir-8558
novel-mir-4078
cgr-miR-342-3p
novel-mir-12547
novel-mir-5393
novel-mir-12388
novel-mir-13041
cgr-miR-183
novel-mir-13139
novel-mir-13583

Negative correlation
cgr-miR-31-5p
cgr-let-7d-3p
cgr-miR-181b-5p
cgr-miR-17-3p
novel-mir-2923

Table 11: Gene ontology and Functional annotation of miR-31-5p target genes predicted by at least
3 in silico tools in combination with DE genes from the RNA-Seq data along with potential genes for
downstream analyses
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Functional group

FDR
(<0.2)

#
Genes Relevant genes to bioprocess

Cytoplasm

0.0002 151

MAPK14, NECAB3, MAP3K2,
PPP2R5A, SMAD3, UBE2I3, EIF5A2

Membrane

0.046

145

TMED10, PPP2R5A, EIF5A2

Cytosol

0.054

48

MAPK14, MAP3K2, PPP2R2A,
PPP2R5A

Endoplasmic reticulum
memb.
0.065

25

TMED10, NECAB3, EIF5A2

Protein phosphatase
type 2A regulator
activity

0.076

5

PPP2R2A, PPP2R5A

Actin binding

0.084

16

Phosphatase activity

0.094

9

Myosin complex

0.094

6

Protein phosphatase
regulator activity

0.1

5

PPP2R2A, PPP2R5A

ATP binding

0.11

41

MAPK14, MAP3K2, UBE2I3

0.12

88

MAPK14, NECAB3, PPP2R5A,
SMAD3

Endoplasmic reticulum 0.16

36

TMED10, NECAB3, EIF5A2

Protein binding

Table 12: Genes selected for downstream analysis from the functional annotation result of miR-31
target genes derived from prediction by at least 3 in silico tools and DE genes from RNA-Seq data.
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Genes
selected

# Times
represented

MAPK14

4

TMED10

3

NECABS

4

MAP3K2

3

PPP2R2A

3

PPP2R5A

6

SMAD3

2

UBE2F

2

EIF5A2

4

Table 13: Functions of potential miR-31-5p target genes with relevance to bioprocess phenotypes
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Genes # Times represented gene ID

MAPK14

4

TMED10

3

NECAB3

4

MAP3K2

3

PPP2R2A

3

PPP2R5A

6

SMAD3

2

UBE2F

2

EIF5A2

4

Functions

augmented expression confer repression of lung cancer growth in vitro and
in vivo. Negatively regulate cell growth and division. Targeting MAPK7 with
miR-143 has been shown to enhance protein production
Involved in vesicular protein trafficking. Mainly functions in the early
secretory pathway
Promotes activation of hypoxia inducible factor-1 (HIF-1) to use glycolysis
even at normal oxygen levels, or normoxia.

Regulate processes such as cell proliferation, cell differentiation, and cell
death in eukaryotes from yeast to humans
Augmented expression confer repression of lung cancer growth in vitro and
in vivo. Negatively regulate cell growth and division
PP2A phosphatase complex, a key negative regulator of the MAP kinase
pathway. PP2A is regulated by the kinase mTOR. Both enzymes affect
phosphorylation status of ribosomal protein S6
The Smad family proteins are critical components of the TGF-β signaling
pathways. TGF-β are inhibitory growth factors and regulates transcriptional
responses
Ubiquitination was initially identified as the main process for protein
degradation. miR-30 overexpression showed decreased SKp2 & Ube2ji mRNA
levels which enhanced protein production in CHO cells
suppression of EIF5A2 in HGC27 cells led to significant decreases in cell
proliferation. EIF5A2 positively regulated cyclin D1 and cyclin D3, which play
important roles in cell proliferation and cell cycle regulation
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Figure 4: qRT-PCR confirmation of 14 DE (FDR<0.05 & FC>2 or <0.5) miRNAs selected from 35
DE (FDR<0.5) miRNAs identified by small RNA-Seq over cell culture duration. MiRNA expression
was normalized to U6 snoRNA. Error bars represent the standard error of mean (SEM) of three
independent experiments (n=3). For statistical analysis, one-way ANOVA comparing the mean
values of the mimics (* P < 0.05; ** P < 0.01; *** P < 0.001).
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Figure 6: Growth profile of CHO-lys-low producer post-transfection with (A) mouse miR-31-5p
mimic (B) mouse miR-31-5p inhibitor (C) Product concentration (titer) of lysosomal enzyme
secreted by CHO-lys-low producer post-transfection of mouse miR-31-5p inhibitor (D) Product
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Figure 7: (A) Functional annotation clustering of DE target genes of miR-31-5p predicted by at
least 3 in silico tools in combination with miRNA-target gene result from the NGS data analyses. (B)
Quantitative real-time PCR (qRT-PCR) analyses of day 3 RNA samples used for NGS for both
CHO-lys-low and CHO-lys-high producer cell lines. mRNA levels of GALC.
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Table 14: Primers used for miRNA and mRNA expression analyses using qRT-PCR

Gene ID
GAPDH
U6 snoRNA
Lysosomal gene
cgr-miR-31-5p

Forward primer (5’ – 3’)
AGCCACATCGCTCAGACAC
CTCGCTTCGGCAGCACA
proprietary
AGGCAAGAUGCUGGCAUAGCUG

Reverse Primer (5’ – 3’)
GCCCAATACGACCAAATCC
AACGCTTCACGAATTTGCGT
proprietary
Qiagen universal reverse
primer

Table 15: miRTarbase (v 7.0) list of validated targets of positively titer-correlating miRNAs unique
to CHO-lys-high producer cell line
miRNA

Validated
targets

Gene description

Gene Functions

mmu-miR10b-5p

Cdkn1a

cyclin-dependent kinase inhibitor
1A

Klf4

Kruppel-like factor 4

Hoxd10

Homeobox D10

Sirt1

Sirtuin 1

Nfkb1

Nuclear factor of kappa light
polypeptide gene enhancer in Bcells

Notch1

Notch 1

Smad4

SMAD family member 4

Inhibits cellular
proliferation
mediated by
p53/TP53 and cyclin
dependent kinase
activity preventing
cell cycle
progression
Inhibition increased
cancer cell migration
Sequence-specific
TF. Inhibition
represses metastasis
in mammary tumor
Maintains metabolic
homeostasis in
adipose tissues
decreased
expression of siah2
(miR-146b target),
inhibits ubiquination
of TRAF proteins
upregulatin NF-kB
Knockdown
promoted stem cell
proliferation in
mouse
Are critical
components of the
TGF-β signaling
pathways. TGF-β are
inhibitory growth
factors and
regulates

mmu-miR146b-5p

76

Validated
method
(miRTarbas
e)
qPCR

References

qPCR

Ma Li,
2010
Ma et al,
2010

WB

Harper et
al, 1993

qPCR, WB,
Reporter
Assay
WB

Ahn et al,
2013

Reporter
assay

Xiao et al,
2015

Reporter
assay, qPCR

Kaji et al,
2001

Nata et al,
2013
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transcriptional
responses
IRF5

mmu-miR409-3p

nil

mmu-miR32-5p

Enpp6

mmu-let-7f

nil

mmu-miR486-5p
mmu-miR192

nil

mmu-miR342-3p
mmu-miR183

interferon regulatory factor 5

ectonucleotide
pyrophosphatase/phosphodiester
ase 6

Zeb2 (SIP1)

zinc finger E-box binding
homeobox 2

H3f3b

H3 histone, family 3B

Key transcription
factor for
macrophage
differentiation
Suppresses cellular
proliferation (Li et al,
2012)
Choline-specific
glycerophosphodiest
er
phosphodiesterase
(uniprot.org)

Reporter
assay

Peng et al,
2016

WB,
Reporter
Assay

Shin et al,
2009

E-box (a DNA
resonse element)
repressor
nucleosome
structural function

qPCR, WB,
Reporter
Assay
qPCR,
Reporter
Assay

Kato et al,
2007

Activation of MAPK
pathway in response
to stress
encodes repressors
of E-cadherin
impairs Wnt/βcatenin signalling
pathway

qPCR

Patel et al,
2013

Reporter
assay
qPCR, WB,
Reporter
Assay

Oba et al,
2013
Chen et al,
2014

Lu et al,
2017

nil
Taok1

TAO kinase 1

Zeb2

zinc finger E-box binding
homeobox 2
low density lipoprotein receptorrelated protein 6

Lrp6
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CHAPTER 5

Inhibitory impact of miR-23a/miR-377 on SUMF1 in CHO
cells enhances difficult-to-express recombinant
lysosomal sulfatase activity

Ifeanyi Michael Amadi1,2, Vishal Agrawal1, Terri Christianson1, Cameron
Bardliving2, Parviz Shamlou2, Jonathan Lebowitz1
1

BioMarin Pharmaceutical Inc. 105 Digital Dr. Novato, California 94949, USA

2

Keck Graduate Institute. 535 Watson Dr. Claremont, California 91711, USA

ABSTRACT
Difficult-to-express (DTE) recombinant proteins like multi-specific proteins, DTE monoclonal
antibodies and lysosomal enzymes, have seen difficulties in manufacturability using
Chinese hamster ovary (CHO) cells and other mammalian cells as production platforms.
CHO cells are preferably used for protein production because of their innate ability to secrete
human-like recombinant proteins with post-translational modification, resistance to viral
infection and familiarity with drug regulators. However, despite huge progress made in
engineering CHO cells for high volumetric productivity, DTE proteins like recombinant
lysosomal sulfatase represent one of the poorly understood proteins. Furthermore, there
are growing interest in the use of microRNA (miRNA) to engineer CHO cells expressing
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DTE proteins to improve cell performance of relevant bioprocess phenotypes. To our
knowledge, no research has been done to improve CHO cell production of DTE recombinant
lysosomal sulfatase using miRNA. We identified miR-23a and miR-377 as miRNAs targeting
SUMF1 using in silico prediction tools as SUMF1 is an activator of sulfatases. Transient
inhibition of endogenous miR-23a/miR-377 significantly enhanced recombinant sulfatase
enzyme specific activity in CHO cell without affecting cell growth. Though, inhibition of miR23a/miR-377 had no significant effect on the mRNA and protein levels of SUMF1,
overexpression of miR-23a/377 significantly reduced both the mRNA and protein levels of
SUMF1. In summary, our data demonstrates the importance of using miRNA to optimize
CHO cell line secreting DTE recombinant lysosomal sulfatase.

Keywords: Chinese hamster ovary (CHO cells), cell engineering, microRNA, lysosomal
protein, sulfatase, miR-23a, miR-377
Abbreviations: CHO, Chinese hamster ovary; DTE, difficult-to-express; SUMF1, sulfatase
modifying factor 1; miRNA, microRNA; UTR, untranslated region; FGE, formylglycine
(FGly)-generating enzyme; qRT-PCR, real-time quantitative reverse-transcription PCR.
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5.0 Introduction
The use of mammalian cells, most especially CHO, as a production platform for recombinant
therapeutic proteins has increased for decades because of its ability to secrete proteins with
similar post-translational modifications (PTM) like humans (Fliedl, Grillari, and GrillariVoglauer 2015). Though significant improvements have been made at increasing specific
and volumetric productivities of cells using media optimizations (Clincke et al. 2011;
Buchsteiner et al. 2018), process improvements (Huang et al. 2010; Gagnon et al. 2011)
and genetic engineering (Jazayeri et al. 2018), there have been limitations especially for
difficult-to-express (DTE) proteins with very low production titers or improper folding
compared to biomanufacturing standards. The production of recombinant therapeutic
lysosomal proteins have not experienced the tremendous improvements in protein
production as seen in most monoclonal antibodies, secreted alkaline phosphatase (SEAP),
and other easy-to-express proteins. Though classical cell engineering of cells has been
done by the overexpression or knockdown of protein coding genes, this approach introduces
additional translational burden and cellular limitations.
In recent years, there has been growing interest in the use of microRNA (miRNA) to
engineer CHO cells for improvement in cell performance of relevant bioprocess phenotypes
(Jadhav et al. 2012; Niall Barron 2012; Jadhav et al. 2013; Stiefel et al. 2016). MiRNAs are
short non-coding RNA molecules, about 18-24 nucleotide long; they negatively regulate
gene expression post-transcriptionally via translation repression or mRNA degradation
without adding any translational burden to the cell machinery unlike protein-coding genes.
In addition, miRNA can regulate an entire network of genes (Galatenko et al. 2018) and it
regulate gene expression by acting as a rheostat (Baek et al. 2008), partially reducing
protein expression unlike small-interfering RNAs (si-RNAs) that most often completely
obliterate their protein target. MiRNA regulate gene expression by binding to the 3’
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untranslated region (UTR) of their mRNA target by using their “seed” region located at the
5’ region of the miRNA. Based on these desirable qualities of miRNA, scientist have
engineered CHO cells to optimize relevant bioprocess phenotypes e.g., apoptosis (Druz et
al. 2013), cell proliferation (Hackl et al. 2014), and specific productivity (Strotbek et al. 2013;
Loh et al. 2014; Meyer et al. 2017; Fischer, Paul, et al. 2015; Loh, Yang, and Lam 2017;
Inwood et al. 2017; Emmerling et al. 2016). However, most of the CHO cell lines used only
secreted easy-to-express recombinant proteins and only of recent has miRNA engineering
of CHO cell line expressing DTE proteins been tested. MiR-143 and miR-557 has been
shown to enhance protein production and improve cell line development respectively in
CHO cell lines expressing DTE monoclonal antibodies (Schoellhorn et al. 2017; Fischer et
al. 2017; Strotbek et al. 2013). MiR-143 exhibited this attribute by repressing mitogenactivated protein kinase (MAPK7) and MAPK pathways has been shown to regulate gene
transcription, protein synthesis and differentiation (Kyriakis and Avruch 2001). In addition,
target gene for miR-557 has not been identified till date.
Previous study (Frankel et al. 2014) demonstrated that by inhibiting miR-95, which regulates
the expression of residual sulfatase modifying factor 1 (SUMF1), sulfatase activity could be
increased. In this study, Frankel et al. transfected human cancer lines and fiboblasts to
demonstrate the effect of miR-95 which is a non-conserved (not found in mice) miRNA.
SUMF1 plays a crucial role in the production of lysosomal sulfatase proteins, since it
encodes Cα-formylglycine (FGly)-generating enzyme (FGE) which activates sulfatases by
converting their cysteine residue to active FGly. In addition, inhibition of miR-23 has been
shown to increase CHO cell productivity by increasing oxidative metabolism (Kelly et al.
2015). However, the CHO cell secretes an easy-to-express SEAP protein which may be
unable to stretch the full capability of the miRNA engineering function.

81

DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD

In this study, we sought to identify and functionally test miRNA(s) that target SUMF1 and
improve recombinant sulfatase specific activity. MiR-23a and miR-377 were identified to
target SUMF1 using in silico computational predictive tools e.g., TargetScan, miRandamirSVR, Diana-microT-CDS, Diana-Tarbase and miRecords. Following this, we used an inhouse CHO cell line stably expressing a recombinant lysosomal sulfatase enzyme for cell
line engineering. Furthermore, transient functional inhibition of endogenous miR-23a/miR377 using miR-23a/miR-377 antimiRs enhanced recombinant sulfatase enzyme specific
activity in CHO-sulfatase cell without affecting cell growth. Though, inhibition of miR23a/miR-377 had no significant effect on the mRNA and protein levels of SUMF1,
overexpression of miR-23a/miR-377 significantly reduced both the mRNA and protein levels
of SUMF1.
5.1

Materials and Methods

5.1.1

Cell culture

CHO suspension cells stably expressing sulfatase protein (CHO-sulfatase) were cultivated
in CD CHO medium (Thermo Scientific, Waltham, MA, USA) and routinely propagated in 6well plates (Life Technologies, Grand Island, New York) and maintained at 37⁰C, 5% CO2
and 80% humidity in a static incubator (Thermo Scientific, Waltham, MA, USA). Inoculation
cells were sourced from cells maintained in 30-60 mL shake flask (Corning, Oneonta, NY,
USA) at 37⁰C, 5% CO2 and 80% humidity in an orbital shaker incubator (Infors HT,
Annapolis Junction, Maryland, USA) with agitation at 125 rpm. Cells were passaged every
3-4 days at a seeding density of 0.5 x 106 cells/mL. Cell concentration and viability were
measured using the ViCellTM (Beckman Coulter, Brea, CA, USA) by the trypan blue
exclusion method. HEK293, HT1080 and MCF7 cells were cultivated in DMEM medium
supplemented with 10% FBS (VWR, Radnor, PA, USA), and 2 mM GlutaMAX TM (Thermo
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Scientific, Waltham, MA, USA). The mammalian cells were routinely propagated in T75
flasks (Corning, Oneonta, NY, USA).

5.1.2

Transfection

Transient transfection of miRNA mimics, inhibitors and siRNAs (Qiagen, Germantown, MD,
USA; Dharmacon, GE Healthcare, Lafayette, CO, USA) were carried out using
LipofectamineTM RNAiMax (Thermo Scientific, Waltham, MA, USA) transfection reagent and
Opti-MEM I (Thermo Scientific, Waltham, MA, USA) reduced serum medium for complex
formation at a final concentration of 50 nM, unless indicated differently. Anti-SUMF1
SMARTpoolTM siRNAs (mouse si-SUMF1) (Dharmacon, GE Healthcare, Lafayette, CO,
USA), which comprises of a mixture of 4 siRNAs, was used as a functional control and the
scramble universal negative control (Sigma-Aldrich, Louis, MO, USA) as a non-targeting
control (NT-siRNA).

5.1.3

RNA Isolation

Total RNA, including small RNA, was extracted using Quick-RNA Microprep kit (Zymo
Research, Irvine, CA, USA) according to the protocol of the manufacturer from samples
harvested from cell culture 48 days post-transfection. The concentration and purity of the
RNA was determined by UV-spectrometry using a DS-11 spectrophotometer (DeNovix,
Wilmington, DE, USA) by measuring absorbance at 230, 260, and 280 nm.
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5.1.4

Real-time Quantitative Reverse-Transcription PCR (qRT-PCR)

Briefly, cDNA was synthesized from 1 μg or 500 ng (where applicable) of total RNA using
miScript II kit (Qiagen, Germantown, MD, USA) for quantification of mature miRNA(s)
expression and Superscript Vilo kit (Invitrogen, Thermo Scientific, Carlsbad, CA, USA) for
gene expression quantification according to the protocol of the manufacturers. For the
quantification of matured miRNAs and gene expression, qRT-PCR was carried out with 101

diluted cDNA on a LightCycler 480 (Roche Molecular Diagnostics, Pleasanton, CA, USA)

using SsofastTM Evagreen® Supermix (BioRad, Hercules, CA, USA) according to the
protocols of the manufacturer. GAPDH and U6 snoRNA were used for the normalization of
gene expression and mature miRNA expression levels respectively. miScript Universal
Reverse Primer (Qiagen, Germantown, MD, USA) was used for mature miRNA analysis.
Details of primers used for qRT-PCR (supporting information Table S1). For the
quantification of relative gene expression, the comparative C(T) method was employed.

5.1.5

Western blot analysis

Protein extraction on harvested cells was done using the M-PER mammalian Protein
Extraction Reagent Kit (Thermo Scientific, Carlsbad, CA, USA) according to the protocol of
the manufacturer. Halt Protease Inhibitor Cocktail (Thermo Scientific, Carlsbad, CA, USA)
was mixed with the extraction solution at a ratio of 1:100 respectively. The total protein of
the protein extract was determined using the bicinchoninic acid (BCA) protein assay
(Thermo Scientific, Carlsbad, CA, USA) according to the protocol of the manufacturer.
Cellular proteins were separated in a 4-12% SDS-polyacrylamide Nupage premade gels
(Thermo Scientific) using a 1X MOPS SDS running buffer. Proteins were transferred from
the gel to a nitrocellulose membrane using the iBlot 2 dry blotting system (Life Technologies)

84

DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD

according to the protocols of the manufacturer. The membranes were allowed to wash in a
blocking buffer (Thermo Scientific) for 1 hour on a shaker at room temperature. The following
primary antibodies: human SUMF1 (1:1000, TA337720, Origene, Rockville, MD, USA),
mouse/human SUMF1 (1:500, MAB2779, R&D Systems), GAPDH (1:5000, PA1-988,
Thermo Scientific), were diluted in blocking buffer and used to probe the membrane
overnight at 4⁰ C on a shaker. Thereafter, the membranes were probed with fluorochromeconjugated secondary antibodies (LICOR Biosciences, Lincoln, Nebraska, USA) and
detected with Odyssey CLx Imaging System (LICOR Biosciences, Lincoln, Nebraska, USA)
after 1 hour of incubation.

5.1.6

Sulfatase enzymatic activity and Elisa assays

For determination of enzymatic activity of sulfatase in sample supernatant, 4methylumbelliferyl (4-MU) sulfate was used as substrate and incubated in 0.2M NaOAc
buffer (pH 5.6). 0.4M phosphate buffer (pH 6.7) was used to stop reaction and fluorescence
was read at 355 nm (excitation) and 460 nm (emission) on a SpectraMax M3 plate reader
(Molecular Devices, San Jose, CA, USA). Sulfatase protein concentration of sample
supernatant was determined using an Elisa assay. Sulfatase was captured in a binding 96well plate, washed and blocked with a washing and blocking buffer respectively. Anti-mouse
HRP antibody was used to bind detection antibody and reaction detected using QuantaBlu
fluorogenic peroxidase substrate kit (Thermo Scientific, Carlsbad, CA, USA) according to
the manufacturer’s protocol. Fluorescence was read at 325 nm (excitation) and 420 nm
(emission) on a SpectraMax M3 plate reader (Molecular Devices, San Jose, CA, USA)
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5.1.7

Bioinformatics

MiRNAs targeting SUMF1 mRNA were determined using computational prediction tools.
The following tools were employed: TargetScan (v.7.1), miRanda-mirSVR (Aug’10), DianamicroT-CDS (v5.0), Diana-Tarbase (v.8) in combination with miRecords (April 27, 2013).
MiRNAs predicted to target SUMF1 in mouse was used since there are no current target
prediction tool for CHO cells. Only potential miRNAs predicted to target SUMF1 mRNA by
at least four prediction tools were considered for downstream functional analysis.

5.2

Results

5.2.1 In silico identification of putative miRNAs targeting SUMF1
Frankel et al (2014) showed that non-conserved miR-95 have an indirect effect on sulfate
metabolism by regulating SUMF1 gene (Frankel et al. 2014). In addition, they found out that
by inhibiting miR-95, the enzymatic activity of Arylsulfatase B (ARSB) is increased. To
improve the specific activity of an in-house CHO cell expressing a sulfatase, we set out to
identify conserved miRNA(s) targeting SUMF1. Overall, 62 microRNAs (Table 17) were
predicted altogether by the four bioinformatics tools used and 234 (includes the 62
microRNAs) by miRecords. Only 6 of the 62 microRNAs predicted by all four prediction tools
were selected for downstream functional studies. Two of these miRNAs (miR-23a-3p and
miR-377-3p) predicted to target SUMF1 were pursued further.

5.2.2 Characterization of different mammalian cells to determine appropriate
SUMF1 antibody
In order to determine the appropriate SUMF1 antibody for this study we went ahead to test
different mammalian cell lines for the expression of endogenous SUMF1 protein. A total of
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four different mammalian cell types were used: CHO, HT1080, HEK 293, and MCF7. For
the CHO cell lines, three different cell types were used. One of the CHO cell line clone stably
expresses a recombinant sulfatase and human SUMF1, the other stably expresses only a
recombinant sulfatase and the last is a parental CHO cell line expressing no recombinant
protein. In addition, the three different SUMF1 antibodies were tested on the mammalian
cell lines in both reduced and non-reduced condition in a Western blot. As expected, the
human anti-SUMF1 antibody only detected the human recombinant SUMF1 stably
expressed by one of the CHO cell lines in both reduced and non-reduced conditions (Figure
8A). In like manner, mouse/human anti-SUMF1 antibody only detected the human
recombinant SUMF1 stably expressed by one of the CHO cell lines in both reduced and
non-reduced conditions except the detection of a small SUMF1 band in HEK 293 cells in
reduced condition. However, mouse anti-SUMF1 antibody detected endogenous SUMF1 in
all cell line tested except for HEK293 in a reduced condition. However, in non-reduced
condition, only the HEK293 and MCF7 endogenous SUMF1 were not detected. In addition,
si-hSUMF1 (siRNA) optimal concentration for transfection was also tested (Figure 14A-B).

5.2.3 Transient transfection of miR-23a and miR-377 mimics reduced SUMF1
protein and mRNA levels with no effect on sulfatase activity
We employed transient transfection to investigate the effect of the two miRNA mimics on
sulfatase enzyme activity in a CHO cell line stably secreting lysosomal sulfatase. We
observed that both mimics caused a reduction in SUMF1 protein (Figure 10A) and mRNA
(Figure 10B) levels. The reduction in SUMF1 protein 48 h post miRNA transfection was
more pronounced in cells transiently transfected with miR-23a compared to the scramble.
Surprisingly, the mimics had no significant effect on the sulfatase enzyme titer (Figure 9B)
and specific activity (Figure 9C). All cells transfected with miRNA mimic had similar cell
growth profiles compared to the scramble (Figure 9A). Next, we tested the effect of various
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concentrations of miR-23a mimics using the following concentrations: 10, 25, 50, 100 and
200 nM. Overall, miR-23a titration concentrations resulted in a decrease in protein (Figure
13B) and mRNA (Figure 13C) levels of SUMF1 with no effect on growth (Figure 13A).
However, the reduction in mRNA levels from 10, 50 and 200 nM of miR-23a mimics was not
significant and including 100 nM of miR-23a mimic at the protein level. Increased levels of
mature miR-23a-3p and/or miR-377-3p were observed 48 h post-transfection following
transient overexpression of miR-23a and/or miR-377 respectively (Figure 10C & Figure
13D).

5.2.4 Transient inhibition of miR-23a and miR-377 enhances recombinant sulfatase
enzyme specific activity in CHO cell line
We sought to investigate the effect of transiently knocking down miR-23a and miR-377
expression on the specific activity of sulfatase stably secreted in a CHO cell line. To do this,
mouse and CHO cells antimiRs were used knowing that they exhibited similar mature miR23a and miR-377 sequences (Figure 8B). Surprisingly, 48 h post-transfection, there was
no striking effect on the protein levels of SUMF1 except for CHO cells transfected with siSUMF1 as a positive control in which SUMF1 levels were highly depleted (Figure 12A).
Likewise, SUMF1 mRNA levels showed no significant differences with the scramble control
except for cgr-miR-377 that showed a significant decrease in SUMF1 mRNA reduction
compared to scramble control (Figure 12B). However, 72 h post-transfection all antimiRs
tested showed a significant increase in sulfatase specific activity except for anti-mmu-miR377-3p (Figure 11C) with no effect on growth (Figure 11A). In addition, there was no
significant differences between the sulfatase titer of all antimiRs tested compared to
scramble except for anti-cgr-miR-377-3p (Figure 11B). Furthermore, as a confirmation of
functional and efficient transfection of antimiRs and siRNAs, mature miRNA levels analyzed
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48 h post transfection showed downregulation of endogenous miR-23a and miR-377
compared to scramble (Figure 12C)

5.3

Discussion

Mammalian cells has become the traditional and classic cell factories used in the production
of biopharmaceutical recombinant therapeutic proteins (Dyson 2016) because of their ability
to make complex glycosylated proteins and familiarity with biotech regulatory bodies.
Among mammalian cells, CHO cell lines most often represent the mammalian cell of choice
for their ease of use and reduced susceptibility to viral infection (Berting, Farcet, and Kreil
2010; Dumont et al. 2016). However, due to growing interest in the demand and
development of difficult-to-express (DTE) recombinant proteins such as bispecific
antibodies, fusion proteins, and lysosomal proteins, current CHO cell lines may require
optimization in order to operate at their optimum capacities. Though cell engineering
approaches, such as single gene engineering (Onitsuka et al. 2018), has been employed to
improve CHO cell performance there have been limitations associated with this (Le Fourn
et al. 2014). Recently, there has been growing interest in the use of miRNAs to engineer
CHO cells for relevant bioprocess phenotypes (Bratkovič et al. 2012), including applications
in transient protein expression (Meyer et al. 2017) and cell line development (Fischer et al.
2017). MiRNAs are short non-coding RNAs that are 18-21 nucleotide long and each miRNA
regulate gene expression by fine tuning the expression of more than one gene, thereby
regulating more than one pathway concomitantly (Fischer, Handrick, et al. 2015). Although,
much of the knowledge about miRNAs have stemmed from research on its regulatory effects
on diseases (most especially cancer), research on its relevance in cell line engineering for
the biomanufacturing of recombinant proteins have started gaining credence. MiRNA
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engineering of CHO cells application has been demonstrated to impact relevant
bioprocessing phenotypes like apoptosis (Druz et al. 2011), proliferation (N. Barron et al.
2011), cell specific productivity (Inwood et al. 2017) and metabolism (Kelly et al. 2015).
Furthermore, current works are looking at using miRNA to engineer mammalian cells
secreting DTE proteins for desirable and relevant bioprocess phenotypes (Xiao et al. 2015;
Fischer et al. 2017; Schoellhorn et al. 2017). To our knowledge, this is the first study where
miRNA has been used to engineer CHO cell line stably expressing a DTE recombinant
therapeutic lysosomal protein – sulfatase. Lysosomal storage disorders (LSD) are genetic
diseases caused by the accumulation of lysosomal substrates in the lysosome due to
mutation in genes encoding lysosomal enzymes responsible for degrading accumulated
substrates in cells (e.g., glycoaminoglycans –GAGs) (Platt 2018). An example of these
diseases among others is multiple sulfatase deficiency (MSD) caused by mutations in
sulfatase modifying factor 1 (SUMF1), a gene that encodes formylglycine –generating
enzyme (FGE) (Garavelli et al. 2014). Interestingly, SUMF1 has been identified as a direct
target of non-conserved miR-95 (Frankel et al. 2014). The authors discovered that by
inhibiting miR-95, residual increase in SUMF1 protein levels in MSD fibroblast cells led to
an increase in lysosomal sulfatase activity. SUMF1 plays a crucial role in activating
sulfatases by converting cysteine residue in the consensus sequence of sulfatases to active
formyl glycine (FGly) (Landgrebe et al. 2003). Although SUMF1 is conserved both in
prokaryotes and eukaryotes (Landgrebe et al. 2003), miR-95 is only conserved in higher
mammals but not in mice. In principle, since SUMF1 is conserved there might exist other
conserved miRNA(s) in mice that might regulate its expression. We sought to identify
miRNA(s) that regulate SUMF1 and the impact on recombinant therapeutic lysosomal
sulfatase specific activity in CHO cell.
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5.3.1 Transient inhibition of miR-23a and miR-377 increases lysosomal recombinant
sulfatase specific activity in CHO cell
MiR-23a and miR-377 were identified as putative miRNAs regulating SUMF1 by using in
silico computational prediction tools: TargetScan, miRanda-mirSVR, Diana-microT-CDS,
Diana-Tarbase and miRecords. We sought to demonstrate functionally if these miRNAs
might improve the specific activity of recombinant lysosomal sulfatase constitutively
expressed in a CHO cell line. Transient inhibition of miR-23a and miR-377 increased the
specific activity of recombinant lysosomal sulfatase protein by 1.2 – 1.3-fold increase
compared to negative control scramble (Figure 11C) without affecting cell growth (Figure
11A). It seems 1.2 – 1.3-fold increase in sulfatase specific activity appears to be moderate
compared to the scramble control, this could be because transient inhibitory effect of
antimiRs dwindle over time. In addition, similar fold increase in sulfatase activity has been
seen after overexpressing SUMF1 gene in a work by Fraldi et al. (2007). In this conjunction,
a stable inhibition of miR-23a/miR-377 could further boost the specific activity of lysosomal
sulfatase protein constitutively expressed in CHO cells. Notably, in a different study (Kelly
et al. 2015), miR-23 was found to enhance the specific productivity of CHO cell expressing
an easy-to-express human secreted alkaline phosphatase (SEAP) protein without affecting
cell growth. The authors went further to demonstrate that the increased specific productivity
of CHO cells after stably inhibiting miR-23 was as a result of enhanced oxidative
phosphorylation through the TCA cycle. In an earlier study, mitochondrial glutaminase levels
in human P-493B lymphoma cells and PC3 prostate cancer cells increased after
downregulation of miR-23a (Gao et al. 2009). Glutamate, which is a product of glutamine
breakdown in the presence of glutaminase, is funneled via the TCA cycle for ATP production
which is very vital for protein synthesis. Furthermore, in a different study, overexpression of
miR-377 caused a 60% reduction in MAP3K7 protein levels (Zehavi et al. 2015) and
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regulation of MAPK7 gene in CHO by miR-143 has been shown to enhance the expression
of a DTE protein (Schoellhorn et al. 2017). Hypothetically, after transient inhibition of miR23a/miR-377 we expected an increase in SUMF1 mRNA and protein levels instead we
observed no significant difference in SUMF1 protein (Figure 12A) and mRNA (Figure 12B)
levels compared to the scramble control. This might be an indication that the right amount
of SUMF1 as needed by the internal cellular mechanism is just right enough to increase the
specific activity of recombinant lysosomal sulfatases while inhibiting the effect of
endogenous miR-23a/miR-377 negatively regulating SUMF1 transcripts. Surprisingly, when
miR-23a and miR-377 were transiently overexpressed, the SUMF1 protein (Figure 10A)
and mRNA (Figure 10B) in CHO cells were significantly decreased compared to the
scramble control. This phenomenon was also confirmed when we performed a titration of
miR-23a mimics concentration and each concentration resulted in a decrease in mRNA
(Figure 13C) and protein levels (Figure 13B) of SUMF1 with no effect on growth (Figure
13A). Though the reduction in mRNA using 10, 50 and 200 nM of miR-23a mimics were not
significant (Figure 13C) and including 100 nM of miR-23a mimic for protein levels (Figure
13B). However, the reduction in mRNA and protein levels of SUMF1 as a result of miR23a/miR-377 overexpression did not cause any decrease in recombinant lysosomal
sulfatase specific activity. The explanation could be that there are other internal cellular
mechanism that maintains a particular threshold of SUMF1 levels (Sardiello et al. 2005) and
the optimal amount of SUMF1 required to activate sulfatases may vary across the different
types of lysosomal sulfatases (Fraldi et al. 2007). In our case, the optimal SUMF1 required
for activation of our sulfatase enzyme of interest might be low which might explain the
reason there was no change in specific activity of the lysosomal sulfatase following the
overexpression of miR23a/miR-377. Taken together, these data demonstrate the relevance
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of miR-23a and miR-377 in cell engineering of CHO cells expressing DTE recombinant
therapeutic lysosomal sulfatase protein.
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FIGURES
A
ANTIBODIES TESTED

Human anti-SUMF1

REDUCED CONDITION

41kDa

Mouse anti-SUMF1

41kDa

Mouse/human
anti-SUMF1

41kDa

NON -REDUCED CONDITION

SUMF1

SUMF1

SUMF1

B

Figure 8: Characterization of different mammalian cells to determine appropriate SUMF1 antibody
(A) Western blot detection of endogenous SUMF1 protein 72 h post transfection. In addition,
SUMF1 protein detection in CHO-sulfatase cell stably expressing human SUMF1 was also tested
(B) Predicted binding sites of miR-23a and miR-377 on SUMF1 3’ UTR. Bases in red represents
the binding site of the miRNAs seed region to the 3’ UTR of SUMF1 (TargetScan.org).
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Figure 9: Transient transfection of 50 nM miR-23a and miR-377 mimics in CHO suspension cells
stably expressing a recombinant difficult-to-express (DTE) lysosomal sulfatase protein. Cells were
cultured in a 6-well plate using a batch process and kept in a static incubator. (A) Viable cell density
(VCD) and viability 72 h post transfection (B) Sulfatase titer and (C) specific activity determined by
an Elisa and activity assay respectively. Samples were taken from the culture supernatants 72 h
post-transfection and data represented as fold change normalized to scramble (NT-siRNA) control.
Anti-SUMF1 siRNA (si-SUMF1) was used as a positive control. Error bars represent the standard
error of mean (SEM) of three independent experiments (n=3). For statistical analysis, one-way
ANOVA comparing the mean values of the mimics (*** P < 0.001).
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Figure 10: Functional validation of SUMF1 as a putative target of miR-23a and miR-377 using
Western blot and quantitative real-time PCR (qRT-PCR) analyses. Cells were transiently
transfected with 50 nM of miR-23a and miR-377 mimics in CHO suspension cells stably expressing
a recombinant difficult-to-express (DTE) lysosomal sulfatase protein and cell lysates harvested 48 h
post-transfection. (A) Western blot showing SUMF1 protein levels and relative densitometry signal
values of SUMF1 protein levels relative to GAPDH (B) Endogenous SUMF1 mRNA levels posttransfection relative to scramble (NT-siRNA) non-targeting control. SUMF1 expression was
normalized to GAPDH (C) Endogenous miR-23a and miR-377 levels post-transfection relative to
scramble. MiRNA expression was normalized to U6 snoRNA. Anti-SUMF1 siRNA (si-SUMF1) was
used as a positive control. Error bars represent the standard error of mean (SEM) of three
independent experiments (n=3). For statistical analysis, one-way ANOVA comparing the mean
values of the mimics (* P < 0.05; ** P < 0.01; *** P < 0.001).
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Figure 11: Transient transfection of 50 nM miR-23a and miR-377 antimiRs in (targeting either
endogenous mouse or CHO miR-23a or miR-377) CHO suspension cells stably expressing a
recombinant difficult-to-express (DTE) lysosomal sulfatase protein. Cells were cultured in a 6-well
plate using a batch process and kept in a static incubator. (A) Viable cell density (VCD) and viability
72 h post transfection (B) Sulfatase titer and (C) specific activity determined by an Elisa and activity
assay respectively. Samples were taken from the culture supernatants 72 h post-transfection and
data represented as fold change normalized to scramble (NT-siRNA) control. Anti-SUMF1 siRNA
(si-SUMF1) was used as a positive control. Error bars represent the standard error of mean (SEM)
of three independent experiments (n=3). For statistical analysis, one-way ANOVA comparing the
mean values of the (* P < 0.05; ** P < 0.01; *** P < 0.001).
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Figure 12: Effect of transient transfection of 50 nM miR-23a and miR-377 antimiRs in (targeting
either endogenous mouse or CHO miR-23a or miR-377) CHO suspension cells stably expressing a
recombinant difficult-to-express (DTE) lysosomal sulfatase protein using Western blot and
quantitative real-time PCR (qRT-PCR) analyses. (A) Western blot of SUMF1 protein levels and
relative densitometry signal values of SUMF1 protein levels relative to GAPDH 48 h post
transfection (B) Endogenous SUMF1 mRNA levels post-transfection relative to scramble (NTsiRNA) non-targeting control. SUMF1 expression was normalized to GAPDH (C) Endogenous miR23a and miR-377 levels 48 h post-transfection relative to scramble. miRNA expression was
normalized to U6 snoRNA. Anti-SUMF1 siRNA (si-SUMF1) was used as a positive control. Error
bars represent the standard error of mean (SEM) of three independent experiments (n=3). Error
bars represent the standard error of mean (SEM) of three independent experiments (n=3). For
statistical analysis, one-way ANOVA comparing the mean values of the (* P < 0.05; ** P < 0.01; ***
P < 0.001).
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Figure 13: Transient transfection of titrated concentration (10-200 nM) of cgr-miR-23a mimics in
CHO suspension cells stably expressing a recombinant difficult-to-express (DTE) lysosomal
sulfatase protein. Cells were cultured in a 6-well plate using a batch process and kept in a static
incubator. (A) Upper panel: Viable cell density (VCD). Lower Panel: Viability. Both 72 h posttransfection (B) Western blot of SUMF1 protein levels and densitometry signal values of SUMF1
protein levels relative to GAPDH 48 h post transfection (C) Endogenous SUMF1 mRNA levels posttransfection relative to scramble (NT-siRNA) non-targeting control. SUMF1 expression was
normalized to GAPDH (D) Endogenous miR-23a levels 48 h post-transfection relative to scramble.
miRNA expression was normalized to U6 snoRNA. Anti-SUMF1 siRNA (si-SUMF1) was used as a
positive control. Data are mean +/- SEM of two independent experiment. For statistical analysis,
unpaired two-tailed t-test was applied (* P < 0.05; ** P < 0.01).
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Supporting Information.
Table 16: Primers used for miRNA and mRNA expression analyses using qRT-PCR

Gene ID
GAPDH
U6 snoRNA
SUMF1
cgr-miR-23a-3p
mmu-miR-23a-3p
cgr-miR-377-3p
mmu-miR-377-3p

Forward primer (5’ – 3’)
AGCCACATCGCTCAGACAC
CTCGCTTCGGCAGCACA
TACCTGTCAAAGGCGCTAAC
AUCACAUUGCCAGGGAUUUCC

Reverse Primer (5’ – 3’)
GCCCAATACGACCAAATCC
AACGCTTCACGAATTTGCGT
CATTCCAGGAGACATGGAGAAC
Qiagen universal reverse
primer
AUCACAUUGCCAGGGAUUUCC
Qiagen universal reverse
primer
UGAAUCACACAAAGGCAACUUUU Qiagen universal reverse
primer
AUCACACAAAGGCAACUUUUGU
Qiagen universal reverse
primer
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Supporting Information
Table 17: MiRNAs predicted to target SUMF1 gene in mouse

Prediction tools used: TargetScan (v.7.1), miRanda-mirSVR (Aug’10), Diana-microT-CDS (v5.0),
Diana-Tarbase (v.8) in combination with miRecords (April 27, 2013)
miRecords predicted 234 mouse miRNAs which includes 62 mouse miRNAs predicted altogether
by the 4 tools to target SUMF1. MiRNAs in “red” were the miRNAs predicted by at least 4 tools
and were selected for further downstream analyses. Only data for miR-23a-3p and miR-377-3p is
reported.
miR-21

miR-377-3p

miR-6373

miR-590-5p

miR-882

miR-690

miR-590-3p

miR-185-5p

miR-743a-3p

miR-329

miR-504

miR-497b

miR-362-3p

miR-133a-3p

miR-1896

miR-181a-5p

miR-133b-3p

miR-350-3p

miR-181b

miR-133c

miR-7240-5p

miR-181c

miR-215-3p

miR-350-5p

miR-181d

miR-7227-3p

miR-291b-3p

miR-23a-3p

miR-669e-3p

miR-7094-3p

miR-23b

miR-330-3p

miR-1224-3p

miR-124-3p

miR-6911-3p

miR-7036b-3p

miR-3074-5p

miR-7002-5p

miR-106b-5p

miR-5625-3p

miR-743b-5p not in found CHO

miR-17-5p

miR-875-3p

miR-20a

miR-3473a

miR-300-3p

miR-20b-5p

miR-3473c

miR-204-5p

miR-93-5p

miR-7678-3p

miR-29-5p

miR-290-5p

miR-3082-3p

miR-22-3p

miR-292-5p

miR-3089-3p

miR-381-3p

miR-3470b

miR-155-5p

miR-106a-5p

not in found CHO

not in found CHO
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Supplementary Figure

Figure 14: si-hSUMF1 was titrated to determine the optimal concentration that will reduce or
completely delete exogenously hSUMF1 stably expressed in CHO cell line secreting a sulfatase: A)
Western blot analysis of different concentration of si-hSUMF1 and volume of transfection reagent
used. B) Relative signal intensity of hSUMF1 levels in CHO cell line exogenously expressing
hSUMF1 compared to mock, scramble and untransfected cells.
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